

(FILE 'HOME' ENTERED AT 13:30:58 ON 06 JUN 2003)

FILE 'USPATFULL, CAPLUS' ENTERED AT 13:31:19 ON 06 JUN 2003

L1 1547 FILE USPATFULL

L2 7069 FILE CAPLUS

TOTAL FOR ALL FILES

L3 8616 S COX-2 OR COX2 OR CYCLOOXYGENASE-2 OR CYCLOOXYGENASE2 OR CYCLO

L4 454 FILE USPATFULL

L5 573 FILE CAPLUS

TOTAL FOR ALL FILES

L6 1027 S 162011-90-7/RN OR 162011-90-7 OR ROFECOXIB OR VIOXX OR (MK 09

L7 576 FILE USPATFULL

L8 745 FILE CAPLUS

TOTAL FOR ALL FILES

L9 1321 S CELECOXIB OR CELEBREX OR (SC58635) OR (SC58635) OR (SC-58635)

L10 454 FILE USPATFULL

L11 573 FILE CAPLUS

TOTAL FOR ALL FILES

L12 1027 S 162011-90-7/RN OR 162011-90-7 OR ROFECOXIB OR VIOXX OR (MK 09

L13 579 FILE USPATFULL

L14 745 FILE CAPLUS

TOTAL FOR ALL FILES

L15 1324 S CELECOXIB OR CELEBREX OR (SC58635) OR (SC58635) OR (SC-58635)

L16 1 FILE USPATFULL

L17 1 FILE CAPLUS

TOTAL FOR ALL FILES

L18 2 S ACUTE MUCOSAL EFFECT

L19 9 FILE USPATFULL

L20 53 FILE CAPLUS

TOTAL FOR ALL FILES

L21 62 S (ACUTE (4A) MUCOSAL (4A) EFFECT?)

L22 57401 FILE USPATFULL

L23 74424 FILE CAPLUS

TOTAL FOR ALL FILES

L24 131825 S FATIGUE

L25 7764 FILE USPATFULL

L26 13345 FILE CAPLUS

TOTAL FOR ALL FILES

L27 21109 S DIARRHEA

L28 7811 FILE USPATFULL

L29 13412 FILE CAPLUS

TOTAL FOR ALL FILES

L30 21223 S DIARRHEA OR (LOOSE STOOL)

L31 163 FILE USPATFULL

L32 53 FILE CAPLUS

TOTAL FOR ALL FILES

L33 216 S (RECTAL BLEEDING)

L34 715 FILE USPATFULL

L35 95 FILE CAPLUS

TOTAL FOR ALL FILES

L36 810 S PROCTITIS

L37 774 FILE USPATFULL

L38 198 FILE CAPLUS

TOTAL FOR ALL FILES

L39 972 S PROCTITIS OR (INFLAMMATION (3A) (RECTUM OR RECTAL))

L40 786 FILE USPATFULL

L41 202 FILE CAPLUS

TOTAL FOR ALL FILES

L42 988 S PROCTITIS OR (INFLAMMATION (3A) (RECTUM OR RECTAL OR ANUS OR

L43 12 FILE USPATFULL

L44 3 FILE CAPLUS

TOTAL FOR ALL FILES

L45 15 S SIGMOIDITIS OR (INHLMAMMATION (4A) SIGMOID? (4A) COLON)

L46 12 FILE USPATFULL
L47 3 FILE CAPLUS
TOTAL FOR ALL FILES
L48 15 S SIGMOIDITIS OR (INHLAMMATION (4A) SIGMOID? (4A) (INTERSTINE O
L49 16 FILE USPATFULL
L50 3 FILE CAPLUS
TOTAL FOR ALL FILES
L51 19 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTERSTINE O
L52 16 FILE USPATFULL
L53 3 FILE CAPLUS
TOTAL FOR ALL FILES
L54 19 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTESTINE OR
L55 1023 FILE USPATFULL
L56 600 FILE CAPLUS
TOTAL FOR ALL FILES
L57 1623 S PROSTATITIS OR (INFLAMMATION (5A) PROSTATE)
L58 1569 FILE USPATFULL
L59 1108 FILE CAPLUS
TOTAL FOR ALL FILES
L60 2677 S CYSTITIS OR (INFLAMMATION (5A) BLADDER)
L61 11019 FILE USPATFULL
L62 13518 FILE CAPLUS
TOTAL FOR ALL FILES
L63 24537 S DERMATITIS OR (INFLAMMATION (5A) SKIN)
L64 437 FILE USPATFULL
L65 426 FILE CAPLUS
TOTAL FOR ALL FILES
L66 863 S (URINARY (3A) FREQUEN?)
L67 2 FILE USPATFULL
L68 5 FILE CAPLUS
TOTAL FOR ALL FILES
L69 7 S L21 (1S) TREAT?
L70 5238 FILE USPATFULL
L71 8341 FILE CAPLUS
TOTAL FOR ALL FILES
L72 13579 S L24 (1S) TREAT?
L73 3578 FILE USPATFULL
L74 3160 FILE CAPLUS
TOTAL FOR ALL FILES
L75 6738 S L30 (1S) TREAT?
L76 79 FILE USPATFULL
L77 18 FILE CAPLUS
TOTAL FOR ALL FILES
L78 97 S L33 (1S) TREAT?
L79 476 FILE USPATFULL
L80 102 FILE CAPLUS
TOTAL FOR ALL FILES
L81 578 S L42 (1S) TREAT?
L82 7 FILE USPATFULL
L83 2 FILE CAPLUS
TOTAL FOR ALL FILES
L84 9 S L51 (1S) TREAT?
L85 677 FILE USPATFULL
L86 267 FILE CAPLUS
TOTAL FOR ALL FILES
L87 944 S L57 (1S) TREAT?
L88 882 FILE USPATFULL
L89 386 FILE CAPLUS
TOTAL FOR ALL FILES
L90 1268 S L60 (1S) TREAT?
L91 7480 FILE USPATFULL
L92 3288 FILE CAPLUS
TOTAL FOR ALL FILES
L93 10768 S L63 (1S) TREAT?

L94 156 FILE USPATFULL
L95 191 FILE CAPLUS
TOTAL FOR ALL FILES
L96 347 S L66 (1S) TREAT?
L97 625 FILE USPATFULL
L98 989 FILE CAPLUS
TOTAL FOR ALL FILES
L99 1614 S L12 OR L15
L100 0 FILE USPATFULL
L101 0 FILE CAPLUS
TOTAL FOR ALL FILES
L102 0 S L99 (3S) L69
L103 3 FILE USPATFULL
L104 1 FILE CAPLUS
TOTAL FOR ALL FILES
L105 4 S L99 (3S) L72
L106 1 FILE USPATFULL
L107 4 FILE CAPLUS
TOTAL FOR ALL FILES
L108 5 S L99 (3S) L75
L109 0 FILE USPATFULL
L110 1 FILE CAPLUS
TOTAL FOR ALL FILES
L111 1 S L99 (3S) L81
L112 0 FILE USPATFULL
L113 0 FILE CAPLUS
TOTAL FOR ALL FILES
L114 0 S L99 (3S) L84
L115 1 FILE USPATFULL
L116 2 FILE CAPLUS
TOTAL FOR ALL FILES
L117 3 S L99 (3S) L87
L118 0 FILE USPATFULL
L119 0 FILE CAPLUS
TOTAL FOR ALL FILES
L120 0 S L99 (3S) L90
L121 0 FILE USPATFULL
L122 8 FILE CAPLUS
TOTAL FOR ALL FILES
L123 8 S L99 (3S) L93
L124 0 FILE USPATFULL
L125 0 FILE CAPLUS
TOTAL FOR ALL FILES
L126 0 S L99 (3S) L96
L127 625 FILE USPATFULL
L128 5 FILE USPATFULL
L129 9 FILE USPATFULL
L130 25 FILE CAPLUS
TOTAL FOR ALL FILES
L131 34 S L21 AND TREAT?
L132 19027 FILE USPATFULL
L133 11676 FILE CAPLUS
TOTAL FOR ALL FILES
L134 30703 S L24 AND TREAT?
L135 7445 FILE USPATFULL
L136 5127 FILE CAPLUS
TOTAL FOR ALL FILES
L137 12572 S L30 AND TREAT?
L138 160 FILE USPATFULL
L139 30 FILE CAPLUS
TOTAL FOR ALL FILES
L140 190 S L33 AND TREAT?
L141 779 FILE USPATFULL
L142 134 FILE CAPLUS

TOTAL FOR ALL FILES
L143 913 S L42 AND TREAT?
L144 16 FILE USPATFULL
L145 3 FILE CAPLUS
TOTAL FOR ALL FILES
L146 19 S L51 AND TREAT?
L147 997 FILE USPATFULL
L148 330 FILE CAPLUS
TOTAL FOR ALL FILES
L149 1327 S L57 AND TREAT?
L150 1524 FILE USPATFULL
L151 558 FILE CAPLUS
TOTAL FOR ALL FILES
L152 2082 S L60 AND TREAT?
L153 10661 FILE USPATFULL
L154 5030 FILE CAPLUS
TOTAL FOR ALL FILES
L155 15691 S L63 AND TREAT?
L156 414 FILE USPATFULL
L157 258 FILE CAPLUS
TOTAL FOR ALL FILES
L158 672 S L66 AND TREAT?
L159 1 FILE USPATFULL
L160 1 FILE CAPLUS
TOTAL FOR ALL FILES
L161 2 S L131 AND L99
L162 58 FILE USPATFULL
L163 2 FILE CAPLUS
TOTAL FOR ALL FILES
L164 60 S L134 AND L99
L165 68 FILE USPATFULL
L166 10 FILE CAPLUS
TOTAL FOR ALL FILES
L167 78 S L137 AND L99
L168 8 FILE USPATFULL
L169 0 FILE CAPLUS
TOTAL FOR ALL FILES
L170 8 S L140 AND L99
L171 5 FILE USPATFULL
L172 2 FILE CAPLUS
TOTAL FOR ALL FILES
L173 7 S L143 AND L99
L174 1 FILE USPATFULL
L175 1 FILE CAPLUS
TOTAL FOR ALL FILES
L176 2 S L146 AND L99
L177 15 FILE USPATFULL
L178 3 FILE CAPLUS
TOTAL FOR ALL FILES
L179 18 S L149 AND L99
L180 17 FILE USPATFULL
L181 1 FILE CAPLUS
TOTAL FOR ALL FILES
L182 18 S L152 AND L99
L183 174 FILE USPATFULL
L184 16 FILE CAPLUS
TOTAL FOR ALL FILES
L185 190 S L155 AND L99
L186 4 FILE USPATFULL
L187 0 FILE CAPLUS
TOTAL FOR ALL FILES
L188 4 S L158 AND L99
L189 241 FILE USPATFULL
L190 29 FILE CAPLUS

TOTAL FOR ALL FILES
L191 270 S L159-L188
L192 75708 FILE USPATFULL
L193 103192 FILE CAPLUS
TOTAL FOR ALL FILES
L194 178900 S L21 OR L24 OR L30 OR L33 OR L42 OR L51 OR L57 OR L60 OR L63 O
L195 8 FILE USPATFULL
L196 35 FILE CAPLUS
TOTAL FOR ALL FILES
L197 43 S L194 (2S) L99
L198 7 FILE USPATFULL
L199 29 FILE CAPLUS
TOTAL FOR ALL FILES
L200 36 S L197 AND L191

FILE 'USPATFULL, CAPLUS' ENTERED AT 13:31:19 ON 06 JUN 2003

L1 1547 FILE USPATFULL

L2 7069 FILE CAPLUS

TOTAL FOR ALL FILES

L3 8616 S COX-2 OR COX2 OR CYCLOOXYGENASE-2 OR CYCLOOXYGENASE2 OR CYCLO

L4 454 FILE USPATFULL

L5 573 FILE CAPLUS

TOTAL FOR ALL FILES

L6 1027 S 162011-90-7/RN OR 162011-90-7 OR ROFECOXIB OR VIOXX OR (MK 09

L7 576 FILE USPATFULL

L8 745 FILE CAPLUS

TOTAL FOR ALL FILES

L9 1321 S CELECOXIB OR CELEBREX OR (SC58635) OR (SC58635) OR (SC-58635)

L10 454 FILE USPATFULL

L11 573 FILE CAPLUS

TOTAL FOR ALL FILES

L12 1027 S 162011-90-7/RN OR 162011-90-7 OR ROFECOXIB OR VIOXX OR (MK 09

L13 579 FILE USPATFULL

L14 745 FILE CAPLUS

TOTAL FOR ALL FILES

L15 1324 S CELECOXIB OR CELEBREX OR (SC58635) OR (SC58635) OR (SC-58635)

L16 1 FILE USPATFULL

L17 1 FILE CAPLUS

TOTAL FOR ALL FILES

L18 2 S ACUTE MUCOSAL EFFECT

L19 9 FILE USPATFULL

L20 53 FILE CAPLUS

TOTAL FOR ALL FILES

L21 62 S (ACUTE (4A) MUCOSAL (4A) EFFECT?)

L22 57401 FILE USPATFULL

L23 74424 FILE CAPLUS

TOTAL FOR ALL FILES

L24 131825 S FATIGUE

L25 7764 FILE USPATFULL

L26 13345 FILE CAPLUS

TOTAL FOR ALL FILES

L27 21109 S DIARRHEA

L28 7811 FILE USPATFULL

L29 13412 FILE CAPLUS

TOTAL FOR ALL FILES

L30 21223 S DIARRHEA OR (LOOSE STOOL)

L31 163 FILE USPATFULL

L32 53 FILE CAPLUS

TOTAL FOR ALL FILES

L33 216 S (RECTAL BLEEDING)

L34 715 FILE USPATFULL

L35 95 FILE CAPLUS

TOTAL FOR ALL FILES

L36 810 S PROCTITIS

L37 774 FILE USPATFULL

L38 198 FILE CAPLUS

TOTAL FOR ALL FILES

L39 972 S PROCTITIS OR (INFLAMMATION (3A) (RECTUM OR RECTAL))

L40 786 FILE USPATFULL

L41 202 FILE CAPLUS

TOTAL FOR ALL FILES

L42 988 S PROCTITIS OR (INFLAMMATION (3A) (RECTUM OR RECTAL OR ANUS OR

L43 12 FILE USPATFULL

L44 3 FILE CAPLUS

TOTAL FOR ALL FILES

L45 15 S SIGMOIDITIS OR (INHLMAMMATION (4A) SIGMOID? (4A) COLON)

L46 12 FILE USPATFULL

L47 3 FILE CAPLUS

TOTAL FOR ALL FILES
L48 15 S SIGMOIDITIS OR (INHLAMMATION (4A) SIGMOID? (4A) (INTERSTINE O
L49 16 FILE USPATFULL
L50 3 FILE CAPLUS
TOTAL FOR ALL FILES
L51 19 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTERSTINE O
L52 16 FILE USPATFULL
L53 3 FILE CAPLUS
TOTAL FOR ALL FILES
L54 19 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTESTINE OR
L55 1023 FILE USPATFULL
L56 600 FILE CAPLUS
TOTAL FOR ALL FILES
L57 1623 S PROSTATITIS OR (INFLAMMATION (5A) PROSTATE)
L58 1569 FILE USPATFULL
L59 1108 FILE CAPLUS
TOTAL FOR ALL FILES
L60 2677 S CYSTITIS OR (INFLAMMATION (5A) BLADDER)
L61 11019 FILE USPATFULL
L62 13518 FILE CAPLUS
TOTAL FOR ALL FILES
L63 24537 S DERMATITIS OR (INFLAMMATION (5A) SKIN)
L64 437 FILE USPATFULL
L65 426 FILE CAPLUS
TOTAL FOR ALL FILES
L66 863 S (URINARY (3A) FREQUEN?)
L67 2 FILE USPATFULL
L68 5 FILE CAPLUS
TOTAL FOR ALL FILES
L69 7 S L21 (1S) TREAT?
L70 5238 FILE USPATFULL
L71 8341 FILE CAPLUS
TOTAL FOR ALL FILES
L72 13579 S L24 (1S) TREAT?
L73 3578 FILE USPATFULL
L74 3160 FILE CAPLUS
TOTAL FOR ALL FILES
L75 6738 S L30 (1S) TREAT?
L76 79 FILE USPATFULL
L77 18 FILE CAPLUS
TOTAL FOR ALL FILES
L78 97 S L33 (1S) TREAT?
L79 476 FILE USPATFULL
L80 102 FILE CAPLUS
TOTAL FOR ALL FILES
L81 578 S L42 (1S) TREAT?
L82 7 FILE USPATFULL
L83 2 FILE CAPLUS
TOTAL FOR ALL FILES
L84 9 S L51 (1S) TREAT?
L85 677 FILE USPATFULL
L86 267 FILE CAPLUS
TOTAL FOR ALL FILES
L87 944 S L57 (1S) TREAT?
L88 882 FILE USPATFULL
L89 386 FILE CAPLUS
TOTAL FOR ALL FILES
L90 1268 S L60 (1S) TREAT?
L91 7480 FILE USPATFULL
L92 3288 FILE CAPLUS
TOTAL FOR ALL FILES
L93 10768 S L63 (1S) TREAT?
L94 156 FILE USPATFULL
L95 191 FILE CAPLUS

TOTAL FOR ALL FILES
L96 347 S L66 (1S) TREAT?
L97 625 FILE USPATFULL
L98 989 FILE CAPPLUS
TOTAL FOR ALL FILES
L99 1614 S L12 OR L15
L100 0 FILE USPATFULL
L101 0 FILE CAPPLUS
TOTAL FOR ALL FILES
L102 0 S L99 (3S) L69
L103 3 FILE USPATFULL
L104 1 FILE CAPPLUS
TOTAL FOR ALL FILES
L105 4 S L99 (3S) L72
L106 1 FILE USPATFULL
L107 4 FILE CAPPLUS
TOTAL FOR ALL FILES
L108 5 S L99 (3S) L75
L109 0 FILE USPATFULL
L110 1 FILE CAPPLUS
TOTAL FOR ALL FILES
L111 1 S L99 (3S) L81
L112 0 FILE USPATFULL
L113 0 FILE CAPPLUS
TOTAL FOR ALL FILES
L114 0 S L99 (3S) L84
L115 1 FILE USPATFULL
L116 2 FILE CAPPLUS
TOTAL FOR ALL FILES
L117 3 S L99 (3S) L87
L118 0 FILE USPATFULL
L119 0 FILE CAPPLUS
TOTAL FOR ALL FILES
L120 0 S L99 (3S) L90
L121 0 FILE USPATFULL
L122 8 FILE CAPPLUS
TOTAL FOR ALL FILES
L123 8 S L99 (3S) L93
L124 0 FILE USPATFULL
L125 0 FILE CAPPLUS
TOTAL FOR ALL FILES
L126 0 S L99 (3S) L96
L127 625 FILE USPATFULL
L128 5 FILE USPATFULL
L129 9 FILE USPATFULL
L130 25 FILE CAPPLUS
TOTAL FOR ALL FILES
L131 34 S L21 AND TREAT?
L132 19027 FILE USPATFULL
L133 11676 FILE CAPPLUS
TOTAL FOR ALL FILES
L134 30703 S L24 AND TREAT?
L135 7445 FILE USPATFULL
L136 5127 FILE CAPPLUS
TOTAL FOR ALL FILES
L137 12572 S L30 AND TREAT?
L138 160 FILE USPATFULL
L139 30 FILE CAPPLUS
TOTAL FOR ALL FILES
L140 190 S L33 AND TREAT?
L141 779 FILE USPATFULL
L142 134 FILE CAPPLUS
TOTAL FOR ALL FILES
L143 913 S L42 AND TREAT?

L144 16 FILE USPATFULL
L145 3 FILE CAPLUS
TOTAL FOR ALL FILES
L146 19 S L51 AND TREAT?
L147 997 FILE USPATFULL
L148 330 FILE CAPLUS
TOTAL FOR ALL FILES
L149 1327 S L57 AND TREAT?
L150 1524 FILE USPATFULL
L151 558 FILE CAPLUS
TOTAL FOR ALL FILES
L152 2082 S L60 AND TREAT?
L153 10661 FILE USPATFULL
L154 5030 FILE CAPLUS
TOTAL FOR ALL FILES
L155 15691 S L63 AND TREAT?
L156 414 FILE USPATFULL
L157 258 FILE CAPLUS
TOTAL FOR ALL FILES
L158 672 S L66 AND TREAT?
L159 1 FILE USPATFULL
L160 1 FILE CAPLUS
TOTAL FOR ALL FILES
L161 2 S L131 AND L99
L162 58 FILE USPATFULL
L163 2 FILE CAPLUS
TOTAL FOR ALL FILES
L164 60 S L134 AND L99
L165 68 FILE USPATFULL
L166 10 FILE CAPLUS
TOTAL FOR ALL FILES
L167 78 S L137 AND L99
L168 8 FILE USPATFULL
L169 0 FILE CAPLUS
TOTAL FOR ALL FILES
L170 8 S L140 AND L99
L171 5 FILE USPATFULL
L172 2 FILE CAPLUS
TOTAL FOR ALL FILES
L173 7 S L143 AND L99
L174 1 FILE USPATFULL
L175 1 FILE CAPLUS
TOTAL FOR ALL FILES
L176 2 S L146 AND L99
L177 15 FILE USPATFULL
L178 3 FILE CAPLUS
TOTAL FOR ALL FILES
L179 18 S L149 AND L99
L180 17 FILE USPATFULL
L181 1 FILE CAPLUS
TOTAL FOR ALL FILES
L182 18 S L152 AND L99
L183 174 FILE USPATFULL
L184 16 FILE CAPLUS
TOTAL FOR ALL FILES
L185 190 S L155 AND L99
L186 4 FILE USPATFULL
L187 0 FILE CAPLUS
TOTAL FOR ALL FILES
L188 4 S L158 AND L99
L189 241 FILE USPATFULL
L190 29 FILE CAPLUS
TOTAL FOR ALL FILES
L191 270 S L159-L188

```
L192      75708 FILE USPATFULL
L193      103192 FILE CAPLUS
      TOTAL FOR ALL FILES
L194      178900 S L21 OR L24 OR L30 OR L33 OR L42 OR L51 OR L57 OR L60 OR L63 O
L195      8 FILE USPATFULL
L196      35 FILE CAPLUS
      TOTAL FOR ALL FILES
L197      43 S L194 (2S) L99
L198      7 FILE USPATFULL
L199      29 FILE CAPLUS
      TOTAL FOR ALL FILES
L200      36 S L197 AND L191
```

```
=> sace all
SACE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> save all
ENTER NAME OR (END):cox2rad/l
L# LIST L1-L200 HAS BEEN SAVED AS 'COX2RAD/L'
```

```
=> save all
ENTER NAME OR (END):cox2rad/l
L# LIST L1-L200 HAS BEEN SAVED AS 'COX2RAD/L'

=> d his

(FILE 'HOME' ENTERED AT 13:30:58 ON 06 JUN 2003)

FILE 'USPATFULL, CAPLUS' ENTERED AT 13:31:19 ON 06 JUN 2003
L1      1547 FILE USPATFULL
L2      7069 FILE CAPLUS
TOTAL FOR ALL FILES
L3      8616 S COX-2 OR COX2 OR CYCLOOXYGENASE-2 OR CYCLOOXYGENASE2 OR CYCLO
L4      454 FILE USPATFULL
L5      573 FILE CAPLUS
TOTAL FOR ALL FILES
L6      1027 S 162011-90-7/RN OR 162011-90-7 OR ROFECOXIB OR VIOXX OR (MK 09
L7      576 FILE USPATFULL
L8      745 FILE CAPLUS
TOTAL FOR ALL FILES
L9      1321 S CELECOXIB OR CELEBREX OR (SC58635) OR (SC58635) OR (SC-58635)
L10     454 FILE USPATFULL
L11     573 FILE CAPLUS
TOTAL FOR ALL FILES
L12     1027 S 162011-90-7/RN OR 162011-90-7 OR ROFECOXIB OR VIOXX OR (MK 09
L13     579 FILE USPATFULL
L14     745 FILE CAPLUS
TOTAL FOR ALL FILES
L15     1324 S CELECOXIB OR CELEBREX OR (SC58635) OR (SC58635) OR (SC-58635)
L16     1 FILE USPATFULL
L17     1 FILE CAPLUS
TOTAL FOR ALL FILES
L18     2 S ACUTE MUCOSAL EFFECT
L19     9 FILE USPATFULL
L20     53 FILE CAPLUS
TOTAL FOR ALL FILES
L21     62 S (ACUTE (4A) MUCOSAL (4A) EFFECT?)
L22     57401 FILE USPATFULL
L23     74424 FILE CAPLUS
TOTAL FOR ALL FILES
L24     131825 S FATIGUE
L25     7764 FILE USPATFULL
L26     13345 FILE CAPLUS
TOTAL FOR ALL FILES
L27     21109 S DIARRHEA
L28     7811 FILE USPATFULL
L29     13412 FILE CAPLUS
TOTAL FOR ALL FILES
L30     21223 S DIARRHEA OR (LOOSE STOOL)
L31     163 FILE USPATFULL
L32     53 FILE CAPLUS
TOTAL FOR ALL FILES
L33     216 S (RECTAL BLEEDING)
L34     715 FILE USPATFULL
L35     95 FILE CAPLUS
TOTAL FOR ALL FILES
L36     810 S PROCTITIS
L37     774 FILE USPATFULL
L38     198 FILE CAPLUS
TOTAL FOR ALL FILES
L39     972 S PROCTITIS OR (INFLAMMATION (3A) (RECTUM OR RECTAL))
L40     786 FILE USPATFULL
L41     202 FILE CAPLUS
TOTAL FOR ALL FILES
```

L42 988 S PROCTITIS OR (INFLAMMATION (3A) (RECTUM OR RECTAL OR ANUS OR
L43 12 FILE USPATFULL
L44 3 FILE CAPLUS
TOTAL FOR ALL FILES
L45 15 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) COLON)
L46 12 FILE USPATFULL
L47 3 FILE CAPLUS
TOTAL FOR ALL FILES
L48 15 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTERSTINE O
L49 16 FILE USPATFULL
L50 3 FILE CAPLUS
TOTAL FOR ALL FILES
L51 19 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTERSTINE O
L52 16 FILE USPATFULL
L53 3 FILE CAPLUS
TOTAL FOR ALL FILES
L54 19 S SIGMOIDITIS OR (INFLAMMATION (4A) SIGMOID? (4A) (INTESTINE OR
L55 1023 FILE USPATFULL
L56 600 FILE CAPLUS
TOTAL FOR ALL FILES
L57 1623 S PROSTATITIS OR (INFLAMMATION (5A) PROSTATE)
L58 1569 FILE USPATFULL
L59 1108 FILE CAPLUS
TOTAL FOR ALL FILES
L60 2677 S CYSTITIS OR (INFLAMMATION (5A) BLADDER)
L61 11019 FILE USPATFULL
L62 13518 FILE CAPLUS
TOTAL FOR ALL FILES
L63 24537 S DERMATITIS OR (INFLAMMATION (5A) SKIN)
L64 437 FILE USPATFULL
L65 426 FILE CAPLUS
TOTAL FOR ALL FILES
L66 863 S (URINARY (3A) FREQUEN?)
L67 2 FILE USPATFULL
L68 5 FILE CAPLUS
TOTAL FOR ALL FILES
L69 7 S L21 (1S) TREAT?
L70 5238 FILE USPATFULL
L71 8341 FILE CAPLUS
TOTAL FOR ALL FILES
L72 13579 S L24 (1S) TREAT?
L73 3578 FILE USPATFULL
L74 3160 FILE CAPLUS
TOTAL FOR ALL FILES
L75 6738 S L30 (1S) TREAT?
L76 79 FILE USPATFULL
L77 18 FILE CAPLUS
TOTAL FOR ALL FILES
L78 97 S L33 (1S) TREAT?
L79 476 FILE USPATFULL
L80 102 FILE CAPLUS
TOTAL FOR ALL FILES
L81 578 S L42 (1S) TREAT?
L82 7 FILE USPATFULL
L83 2 FILE CAPLUS
TOTAL FOR ALL FILES
L84 9 S L51 (1S) TREAT?
L85 677 FILE USPATFULL
L86 267 FILE CAPLUS
TOTAL FOR ALL FILES
L87 944 S L57 (1S) TREAT?
L88 882 FILE USPATFULL
L89 386 FILE CAPLUS
TOTAL FOR ALL FILES

L90 1268 S L60 (1S) TREAT?
L91 7480 FILE USPATFULL
L92 3288 FILE CAPLUS
TOTAL FOR ALL FILES
L93 10768 S L63 (1S) TREAT?
L94 156 FILE USPATFULL
L95 191 FILE CAPLUS
TOTAL FOR ALL FILES
L96 347 S L66 (1S) TREAT?
L97 625 FILE USPATFULL
L98 989 FILE CAPLUS
TOTAL FOR ALL FILES
L99 1614 S L12 OR L15
L100 0 FILE USPATFULL
L101 0 FILE CAPLUS
TOTAL FOR ALL FILES
L102 0 S L99 (3S) L69
L103 3 FILE USPATFULL
L104 1 FILE CAPLUS
TOTAL FOR ALL FILES
L105 4 S L99 (3S) L72
L106 1 FILE USPATFULL
L107 4 FILE CAPLUS
TOTAL FOR ALL FILES
L108 5 S L99 (3S) L75
L109 0 FILE USPATFULL
L110 1 FILE CAPLUS
TOTAL FOR ALL FILES
L111 1 S L99 (3S) L81
L112 0 FILE USPATFULL
L113 0 FILE CAPLUS
TOTAL FOR ALL FILES
L114 0 S L99 (3S) L84
L115 1 FILE USPATFULL
L116 2 FILE CAPLUS
TOTAL FOR ALL FILES
L117 3 S L99 (3S) L87
L118 0 FILE USPATFULL
L119 0 FILE CAPLUS
TOTAL FOR ALL FILES
L120 0 S L99 (3S) L90
L121 0 FILE USPATFULL
L122 8 FILE CAPLUS
TOTAL FOR ALL FILES
L123 8 S L99 (3S) L93
L124 0 FILE USPATFULL
L125 0 FILE CAPLUS
TOTAL FOR ALL FILES
L126 0 S L99 (3S) L96
L127 625 FILE USPATFULL
L128 5 FILE USPATFULL
L129 9 FILE USPATFULL
L130 25 FILE CAPLUS
TOTAL FOR ALL FILES
L131 34 S L21 AND TREAT?
L132 19027 FILE USPATFULL
L133 11676 FILE CAPLUS
TOTAL FOR ALL FILES
L134 30703 S L24 AND TREAT?
L135 7445 FILE USPATFULL
L136 5127 FILE CAPLUS
TOTAL FOR ALL FILES
L137 12572 S L30 AND TREAT?
L138 160 FILE USPATFULL

L139 30 FILE CAPPLUS
TOTAL FOR ALL FILES
L140 190 S L33 AND TREAT?
L141 779 FILE USPATFULL
L142 134 FILE CAPPLUS
TOTAL FOR ALL FILES
L143 913 S L42 AND TREAT?
L144 16 FILE USPATFULL
L145 3 FILE CAPPLUS
TOTAL FOR ALL FILES
L146 19 S L51 AND TREAT?
L147 997 FILE USPATFULL
L148 330 FILE CAPPLUS
TOTAL FOR ALL FILES
L149 1327 S L57 AND TREAT?
L150 1524 FILE USPATFULL
L151 558 FILE CAPPLUS
TOTAL FOR ALL FILES
L152 2082 S L60 AND TREAT?
L153 10661 FILE USPATFULL
L154 5030 FILE CAPPLUS
TOTAL FOR ALL FILES
L155 15691 S L63 AND TREAT?
L156 414 FILE USPATFULL
L157 258 FILE CAPPLUS
TOTAL FOR ALL FILES
L158 672 S L66 AND TREAT?
L159 1 FILE USPATFULL
L160 1 FILE CAPPLUS
TOTAL FOR ALL FILES
L161 2 S L131 AND L99
L162 58 FILE USPATFULL
L163 2 FILE CAPPLUS
TOTAL FOR ALL FILES
L164 60 S L134 AND L99
L165 68 FILE USPATFULL
L166 10 FILE CAPPLUS
TOTAL FOR ALL FILES
L167 78 S L137 AND L99
L168 8 FILE USPATFULL
L169 0 FILE CAPPLUS
TOTAL FOR ALL FILES
L170 8 S L140 AND L99
L171 5 FILE USPATFULL
L172 2 FILE CAPPLUS
TOTAL FOR ALL FILES
L173 7 S L143 AND L99
L174 1 FILE USPATFULL
L175 1 FILE CAPPLUS
TOTAL FOR ALL FILES
L176 2 S L146 AND L99
L177 15 FILE USPATFULL
L178 3 FILE CAPPLUS
TOTAL FOR ALL FILES
L179 18 S L149 AND L99
L180 17 FILE USPATFULL
L181 1 FILE CAPPLUS
TOTAL FOR ALL FILES
L182 18 S L152 AND L99
L183 174 FILE USPATFULL
L184 16 FILE CAPPLUS
TOTAL FOR ALL FILES
L185 190 S L155 AND L99
L186 4 FILE USPATFULL

L187 0 FILE CAPLUS
TOTAL FOR ALL FILES
L188 4 S L158 AND L99
L189 241 FILE USPATFULL
L190 29 FILE CAPLUS
TOTAL FOR ALL FILES
L191 270 S L159-L188
L192 75708 FILE USPATFULL
L193 103192 FILE CAPLUS
TOTAL FOR ALL FILES
L194 178900 S L21 OR L24 OR L30 OR L33 OR L42 OR L51 OR L57 OR L60 OR L63 O
L195 8 FILE USPATFULL
L196 35 FILE CAPLUS
TOTAL FOR ALL FILES
L197 43 S L194 (2S) L99
L198 7 FILE USPATFULL
L199 29 FILE CAPLUS
TOTAL FOR ALL FILES
L200 36 S L197 AND L191
SAVE ALL COX2RAD/L

L200 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2001:904209 CAPLUS

DN 136:31724

TI Heterocycle derivatives and methods of use

IN Peterson, Johnny W.; Gessell-Lee, Deborah L.; Saini, Shamsher S.

PA The University of Texas System, USA

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H019-20

CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001094369	A2	20011213	WO 2001-US16190	20010519
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002032228	A1	20020314	US 2001-860652	20010519
	US 20020188016	A9	20021212		
PRAI	US 2000-210412P	P	20000608		
OS	MARPAT	136:31724			
AB	The present invention provides methods for treating intestinal fluid loss, whooping cough, anthrax, and conditions assocd. with smooth muscle contraction. The present invention also provides methods for inhibiting adenylylate cyclase in vivo and in vitro.				
ST	heterocycle deriv adenylylate cyclase inhibition diarrhea ; intestinal fluid loss treatment heterocycle deriv; smooth muscle contraction inhibition heterocycle deriv; whooping cough treatment heterocycle deriv				
IT	Animal cell (adenylylate cyclase-contg.; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)				
IT	Prostaglandins RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (analogs; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)				
IT	Bacillus anthracis (anthrax from; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)				
IT	Heterocyclic compounds RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (arom., di-Ph; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)				
IT	ADP ribosylation (by pathogenic organisms; heterocycle derivs. for inhibiting adenylylate				

cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (cholera, intestinal fluid loss stimulation by; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Intestine, disease
(fluid loss; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Antidiarrheals
Pertussis
(heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Heterocyclic compounds
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Aromatic compounds
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic, di-Ph; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Intestine, disease
(infection, fluid loss assocd. with pathogenic; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Pathogen
(intestinal fluid loss assocd. with; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Body fluid
(loss; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Muscle relaxants
(smooth; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 56-65-5, 5'-ATP, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cAMP formation from; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 363-24-6, PGE2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cAMP formation stimulation by and reaction with L-histidine; heterocycle derivs. for inhibiting adenylylate cyclase and methods of use for **treating** intestinal fluid loss and whooping cough and anthrax)

IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation; heterocycle derivs. for inhibiting adenylate cyclase and
methods of use for **treating** intestinal fluid loss and
whooping cough and anthrax and conditions assocd. with smooth muscle
contraction)

IT 9012-42-4, Adenylate cyclase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heterocycle derivs. for inhibiting adenylate cyclase and methods of
use for **treating** intestinal fluid loss and whooping cough and
anthrax and conditions assocd. with smooth muscle contraction)

IT 380153-74-2 380153-75-3
RL: DMA (Drug mechanism of action); FMU (Formation, unclassified); PAC
(Pharmacological activity); THU (Therapeutic use); BIOL (Biological
study); FORM (Formation, nonpreparative); USES (Uses)
(heterocycle derivs. for inhibiting adenylate cyclase and methods of
use for **treating** intestinal fluid loss and whooping cough and
anthrax and conditions assocd. with smooth muscle contraction)

IT 53-86-1, Indomethacin 71-00-1, L-Histidine, biological studies
288-32-4, Imidazole, biological studies 443-48-1, Metronidazole
88149-94-4 162011-90-7 169590-42-5 188817-13-2
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocycle derivs. for inhibiting adenylate cyclase and methods of
use for **treating** intestinal fluid loss and whooping cough and
anthrax and conditions assocd. with smooth muscle contraction)

L200 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 2001:857055 CAPLUS
DN 136:194000
TI **Celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the
severity of experimental colitis induced by dinitrobenzene sulfonic acid
in rats
AU Cuzzocrea, Salvatore; Mazzon, Emanuela; Serraino, Ivana; Dugo, Laura;
Centorrino, Tommaso; Ciccolo, Antonio; Sautebin, Lidia; Caputi, Achille P.
CS Institute of Pharmacology, School of Medicine, University of Messina,
Torre Biologica, Policlinico Universitario Via C. Valera, Gazzi, Messina,
98100, Italy
SO European Journal of Pharmacology (2001), 431(1), 91-102
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-9 (Pharmacology)
AB Inflammatory bowel disease is characterized by oxidative and nitrosative
stress, leukocyte infiltration, upregulation of the expression of
intercellular adhesion mol. 1 (ICAM-1) and upregulation of P-selectin in
the colon. Here, we investigate the effects of the selective
cyclo-oxygenase-2 inhibitor, **celecoxib**, in rats subjected to
exptl. colitis. Colitis was induced in rats by intracolonic instillation
of dinitrobenzene sulfonic acid (DNBS). Rats experienced hemorrhagic
diarrhea and wt. loss. At 4 days after administration of DNBS,
the mucosa of the colon exhibited large areas of necrosis. Neutrophil
infiltration (detd. by histol., as well as an increase in myeloperoxidase
activity in the mucosa) was assocd. with upregulation of ICAM-1 and
P-selectin, as well as high tissue levels of malondialdehyde.
Immunohistochem. for nitrotyrosine and poly(ADP-ribose) polymerase showed
intense staining in the inflamed colon. **Celecoxib** (5 mg/kg
twice a day orally) significantly reduced the degree of hemorrhagic
diarrhea and the wt. loss caused by administration of DNBS.
Celecoxib also caused a substantial redn. of (i) the degree of
colonic injury, (ii) the rise in myeloperoxidase activity (mucosa), (iii)
the increase in the tissue levels of malondialdehyde, (iv) the increase in
staining (immunohistochem.) for nitrotyrosine, as well as (v) the

upregulation of ICAM-1 and P-selectin caused by DNBS in the colon. Thus, we provide the first evidence that a selective cyclo-oxygenase-2 inhibitor **celecoxib** reduces the degree of colitis caused by DNBS.

ST **celecoxib** colitis treatment
IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ICAM-1 (intercellular adhesion mol. 1); **celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT Selectins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (P-; **celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT Oxidative stress, biological
(**celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT Intestine, disease
(colitis; **celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT Neutrophil
(infiltration; **celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT Stress, animal
(nitrosative; **celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT 9003-99-0, Myeloperoxidase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)
IT 169590-42-5, Celecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (**celecoxib**, a selective cyclo-oxygenase-2 inhibitor reduces the severity of exptl. colitis induced by dinitrobenzene sulfonic acid in rats)

RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ajuebor, M; Am J Physiol: Gastrointest Liver Physiol 2000, V279, PG238 CAPLUS
- (2) Allgayer, H; Gastroenterology 1989, V96, P1290 CAPLUS
- (3) Andborn, W; Inflammatory Bowel Dis 1999, V2, P119
- (4) Bjarnson, I; Gastroenterology 1993, V104, P1832
- (5) Bradford, M; Anal Biochem 1976, V72, P248 CAPLUS
- (6) Carty, E; Gut 2000, V46, P487 CAPLUS
- (7) Challa, A; Carcinogenesis 1997, V18, P2023 CAPLUS
- (8) Chan, C; J Pharmacol Exp Ther 1995, V274, P1531 CAPLUS
- (9) Chanvitayapongs, S; NeuroReport 1997, V8, P1499 CAPLUS
- (10) Cohn, S; J Clin Invest 1997, V99, P1327
- (11) Cuzzocrea, S; J Immunol 1999, V22, P5094
- (12) Dreiser, R; Drugs 1993, V46, P270
- (13) Duthie, S; Eur J Nutr 1999, V38, P28 CAPLUS
- (14) D'Haens, G; Gastroenterology 1999, V116, P1029 CAPLUS
- (15) Eiserich, J; Nature 1998, V391, P393 CAPLUS
- (16) Fedorak, R; Gastroenterology 1990, V98, P615 CAPLUS
- (17) Fries, W; Lab Invest 1999, V79, P49 MEDLINE
- (18) Fukuda, K; J Ethnopharmacol 1999, V66, P227 CAPLUS
- (19) Gibson, G; Arch Intern Med 1992, V152, P625 MEDLINE
- (20) Goldstein, J; Am J Gastroenterol 2000, V95, P1681 CAPLUS

(21) Grisham, M; Lancet 1994, V344, P859 MEDLINE
 (22) Halliwell, B; FEBS Lett 1997, V411, P157 CAPLUS
 (23) Hoult, J; Br J Pharmacol 1978, V64, P6 CAPLUS
 (24) Jozeau, J; Drugs 1997, V53, P563
 (25) Karmeli, F; Eur J Gastroenterol Hepatol 2000, V12, P223 CAPLUS
 (26) Kaufmann, H; Ann Intern Med 1987, V107, P513 MEDLINE
 (27) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
 (28) Lesch, C; Methods Find Exp Clin Pharmacol 1999, V21, P99 CAPLUS
 (29) Marcinkiewicz, J; Cytokine 1991, V3, P327 CAPLUS
 (30) Marini, U; Drugs 1993, V46, P249
 (31) Masferrer, J; Gastroenterol Clin North Am 1996, V25, P363 MEDLINE
 (32) McKenzie, S; J Clin Invest 1996, V98, P136 CAPLUS
 (33) Mizuno, H; Gastroenterology 1997, V112, P645
 (34) Moreland, L; J Rheumatol 1996, V23, P1849 CAPLUS
 (35) Mullane, K; J Pharmacol Methods 1985, V14, P157 CAPLUS
 (36) Narisawa, T; Jpn J Cancer Res 1993, V84, P1007 CAPLUS
 (37) Negoro, K; Gastroenterology 1999, V117, P1062 CAPLUS
 (38) Ohkawa, H; Anal Biochem 1979, V95, P351 CAPLUS
 (39) O'Banion, M; J Biol Chem 1991, V266, P23261 CAPLUS
 (40) Present, D; N Engl J Med 1999, V340, P1398 CAPLUS
 (41) Rachmilewitz, D; Gastroenterology 1989, V97, P326 CAPLUS
 (42) Reuter, B; J Clin Invest 1996, V98, P483
 (43) Ricart, E; Gasteroenterology 1999, V117, P429 MEDLINE
 (44) Seibert, K; Proc Natl Acad Sci USA 1994, V91, P12013 CAPLUS
 (45) Sharon, P; Gastroenterology 1978, V75, P638 CAPLUS
 (46) Shiratora, Y; Digestion 1989, V44, P163 MEDLINE
 (47) Simmonds, N; Gastroenterology 1992, V1, P186
 (48) Szabo, C; J Exp Med 1997, V186, P1041 CAPLUS
 (49) Szabo, C; Trends Pharmacol Sci 1998, V19, P287 CAPLUS
 (50) Targan, S; N Engl J Med 1997, V337, P1029 CAPLUS
 (51) Tessner, T; Gastroenterology 1998, V115, P874 CAPLUS
 (52) Tsujii, M; Proc Natl Acad Sci USA 1997, V94, P3336 CAPLUS
 (53) Urthy, S; Aliment Pharmacol Ther 1999, V13, P251
 (54) Wallace, J; Gastroenterology 1992, V102, P18 CAPLUS
 (55) Wallace, J; Gastroenterology 1998, V115, P101 CAPLUS
 (56) Whittle, B; Scand J Gastroenterol, Suppl 1986, V125, P128 MEDLINE
 (57) Xie, W; Drug Dev Res 1992, V25, P249 CAPLUS
 (58) Yamada, T; Inflammation 1993, V17, P641 CAPLUS
 (59) Zhang, F; Carcinogenesis 1999, V20, P445 CAPLUS
 (60) Zingarelli, B; Gastroenterology 1999, V116, P335 CAPLUS

L200 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2001:167798 CAPLUS

DN 134:202695

TI Method for **treating or preventing chronic prostatitis**
 or chronic pelvic pain syndrome with COX-2 selective inhibitor
 IN Nickel, Curtis J.; Stoner, Elizabeth; Waldstreicher, Joanne; Pontari,
 Michel A.
 PA Merck & Co., Inc., USA; Temple University - of the Commonwealth System of
 Higher Education
 SO PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-18
 CC 1-7 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015687	A1	20010308	WO 2000-US23100	20000824
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,			

SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6403640 B1 20020611 US 2000-644998 20000824
EP 1212051 A1 20020612 EP 2000-961351 20000824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
PRAI US 1999-151126P P 19990827
WO 2000-US23100 W 20000824
AB The use of a COX-2 selective inhibitor for the **treatment** or
prevention of chronic **prostatitis** or chronic pelvic pain
syndrome is disclosed.
ST COX2 inhibitor **prostatitis** chronic pelvic pain syndrome;
cyclooxygenase 2 inhibitor **treatment** chronic **prostatitis**
IT Prostate-specific antigen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, in combination with COX-2 inhibitor; COX-2 selective
inhibitor for **treatment** or prevention of chronic
prostatitis or chronic pelvic pain syndrome)
IT Analgesics
Antibiotics
Cholinergic antagonists
(in combination with COX-2 inhibitor; COX-2 selective inhibitor for
treatment or prevention of chronic **prostatitis** or
chronic pelvic pain syndrome)
IT Body, anatomical
(pelvis, chronic pelvic pain syndrome; COX-2 selective inhibitor for
treatment or prevention of chronic **prostatitis** or
chronic pelvic pain syndrome)
IT Prostate gland
(**prostatitis**; COX-2 selective inhibitor for **treatment**
or prevention of chronic **prostatitis** or chronic pelvic pain
syndrome)
IT Drug delivery systems
(topical, urinary analgesics, in combination with COX-2 inhibitor;
COX-2 selective inhibitor for **treatment** or prevention of
chronic **prostatitis** or chronic pelvic pain syndrome)
IT Adrenoceptor antagonists
(.alpha.1-, in combination with COX-2 inhibitor; COX-2 selective
inhibitor for **treatment** or prevention of chronic
prostatitis or chronic pelvic pain syndrome)
IT 51803-78-2, Nimesulide 71125-38-7, Meloxicam 80937-31-1, Flosulide
88149-94-4, DuP 697 123653-11-2, NS 398 162011-90-7,
Rofecoxib 162054-19-5, SC-58125 169590-42-5,
Celecoxib 179382-91-3, RS 57067 181695-72-7, Valdecoxib
198470-84-7, Parecoxib 202409-33-4, MK-663
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(COX-2 selective inhibitor for **treatment** or prevention of
chronic **prostatitis** or chronic pelvic pain syndrome)
IT 39391-18-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)
(cyclooxygenase-2, selective inhibitors; COX-2 selective inhibitor for
treatment or prevention of chronic **prostatitis** or
chronic pelvic pain syndrome)
IT 9081-34-9, 5.alpha.-Reductase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(inhibitors, in combination with COX-2 inhibitor; COX-2 selective
inhibitor for **treatment** or prevention of chronic
prostatitis or chronic pelvic pain syndrome)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aotsuka; US 6136831 A 2000 CAPLUS
- (2) Canale; Andrologia 1993, V25(3), P163 MEDLINE
- (3) Canale; Drugs 1993, Suppl 1, P147
- (4) Grelan Pharmaceutical Co Ltd; WO 9846594 A1 1998 CAPLUS
- (5) Guess; US 6054455 A 2000 CAPLUS
- (6) Melis; Minerva Ginecologica 1997, V49(9), P409 MEDLINE
- (7) Venturini; Cephalalgia 1997, V17/20(29-30)

L200 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2000:900773 CAPLUS

DN 134:41979

TI (Z)-Styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors

IN Reddy, E. Premkumar; Reddy, M. V. Ramana

PA Temple University - of the Commonwealth System of Higher Education, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English


IC ICM C12N

CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1, 7, 35, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000077169	A2	20001221	WO 2000-US16725	20000616
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000056207	A5	20010102	AU 2000-56207	20000616
	EP 1191929	A2	20020403	EP 2000-941505	20000616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-139445P	P	19990616		
	WO 2000-US16725	W	20000616		
OS	MARPAT	134:41979			
GI					



AB (Z)-Styryl acetoxyphenyl sulfides (shown as I; R1, R2, R3, R4 = H, halogen, OH, C1-C8 alkyl, C1-C6 alkoxy, NO₂, CN, OAc, amino, carboxy, sulfamyl, lower acylsulfamyl and trifluoromethyl), a method for their prepn., and their usefulness in **treating** inflammation and

cyclooxygenase-mediated disorders are claimed. The compds. of the invention preferably are characterized by a large selectivity ratio for cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition; data are reported for I (R1 = R2 = R3 = H; R4 = H, 4-F, 2-Cl, 4-Cl, 3-acetoxy). The claimed method of prepn. comprises reacting (Z)-styryl hydroxyphenyl sulfides with acetic anhydride. The (Z)-styryl hydroxyphenyl sulfides were made from sodium 2-hydroxybenzenethiols and phenylacetylenes. I undergo radical polymn. to give polyolefins. (Z)-styryl acetoxyphenyl sulfide was significantly more effective than **Celecoxib** with respect to inhibition of colorectal cancer cell colony growth.

ST styryl acetoxyphenyl sulfide prepn inhibition cyclooxygenase 2 polymn; antiinflammatory cyclooxygenase 2 inhibition styryl acetoxyphenyl sulfide prepn; antitumor agent cyclooxygenase 2 inhibition styryl acetoxyphenyl sulfide prepn; angiogenesis inhibitor cyclooxygenase 2 inhibition styryl acetoxyphenyl sulfide prepn

IT Bronchi
(bronchitis; prepn. of styryl acetoxyphenyl sulfides useful as inhibitors of cyclooxygenase-2 for **treating**)

IT Digestive tract
(disease; prepn. of styryl acetoxyphenyl sulfides useful as inhibitors of cyclooxygenase-2 for **treating**)

IT Drug delivery systems
(of styryl acetoxyphenyl sulfides useful as selective inhibitors of cyclooxygenase-2)

IT Polyolefins
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. by radical polymn. of styryl acetoxyphenyl sulfides)

IT Antitumor agents
(prepn. of styryl acetoxyphenyl sulfides useful against neoplasias that produce prostaglandins)

IT Burn
Dermatitis
Psoriasis
(prepn. of styryl acetoxyphenyl sulfides useful as inhibitors of cyclooxygenase-2 for **treating**)

IT Analgesics
Angiogenesis inhibitors
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antipyretics
Antiviral agents
(prepn. of styryl acetoxyphenyl sulfides useful as selective inhibitors of cyclooxygenase-2)

IT Thioethers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of styryl acetoxyphenyl sulfides useful as selective inhibitors of cyclooxygenase-2)

IT Tendon
(tendinitis; prepn. of styryl acetoxyphenyl sulfides useful as inhibitors of cyclooxygenase-2 for **treating**)

IT 536-74-3, Phenylacetylene 766-96-1, 4-Bromophenylacetylene 766-97-2, 4-Methylphenylacetylene 766-98-3, 4-Fluorophenylacetylene 768-60-5, 4-Methoxyphenylacetylene 873-31-4, 2-Chlorophenylacetylene 873-73-4, 4-Chlorophenylacetylene 937-31-5, 4-Nitrophenylacetylene 10401-11-3, 3-Hydroxyphenylacetylene 40307-11-7, 4-Ethylphenylacetylene 79887-10-8, 4-Pentylphenylacetylene
RL: RCT (Reactant); RACT (Reactant or reagent)
(addn. reactions with 2-acetoxythiophenols in presence of sodium followed by condensation with acetic anhydride)

IT 313269-75-9, 2-Acetoxybenzenethiol
RL: RCT (Reactant); RACT (Reactant or reagent)

IT (addn. reactions with phenylacetylenes in presence of sodium)
1121-24-0, 2-Hydroxythiophenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(addn. reactions with phenylacetylenes in presence of sodium followed
by condensation with acetic anhydride)

IT 39391-18-9
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(cyclooxygenase-2; prepn. of styryl acetoxyphenyl sulfides useful as
selective inhibitors of cyclooxygenase-2 relative to cyclooxygenase-1)

IT 313269-63-5P, (Z)-Styryl 2-acetoxyphenyl sulfide 313269-64-6P,
(Z)-4-Fluorostyryl 2-acetoxyphenyl sulfide 313269-65-7P,
(Z)-2-Chlorostyryl 2-acetoxyphenyl sulfide 313269-66-8P,
(Z)-4-Chlorostyryl 2-acetoxyphenyl sulfide 313269-72-6P,
(Z)-3-Acetoxystyryl 2-acetoxyphenyl sulfide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of styryl acetoxyphenyl sulfides useful as selective inhibitors
of cyclooxygenase-2)

IT 313269-67-9P, (Z)-4-Bromostyryl 2-acetoxyphenyl sulfide 313269-68-0P,
(Z)-4-Methylstyryl 2-acetoxyphenyl sulfide 313269-69-1P,
(Z)-4-Ethylstyryl 2-acetoxyphenyl sulfide 313269-70-4P,
(Z)-4-Pentylstyryl 2-acetoxyphenyl sulfide 313269-71-5P,
(Z)-3-Hydroxystyryl 2-acetoxyphenyl sulfide 313269-73-7P,
(Z)-4-Methoxystyryl 2-acetoxyphenyl sulfide 313269-74-8P,
(Z)-4-Nitrostyryl 2-acetoxyphenyl sulfide
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(prepn. of styryl acetoxyphenyl sulfides useful as selective inhibitors
of cyclooxygenase-2)

L200 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 2000:757695 CAPLUS
DN 134:65940
TI Topical application of a selective cyclooxygenase inhibitor suppresses UVB
mediated cutaneous inflammation
AU Wilgus, Traci A.; Ross, Mary S.; Parrett, Michelle L.; Oberyszyn, Tatiana
M.
CS Department of Molecular Virology, Immunology and Medical Genetics, The
College of Medicine, The Ohio State University, Columbus, OH, 43210, USA
SO Prostaglandins & Other Lipid Mediators (2000), 62(4), 367-384
CODEN: POLMFL; ISSN: 1098-8823
PB Elsevier Science Inc.
DT Journal
LA English
CC 1-7 (Pharmacology)
Section cross-reference(s): 8
AB This work compared the effects of topical **celecoxib** with
ibuprofen (a nonspecific COX inhibitor) on the acute UVB-induced cutaneous
inflammatory response in mice. The specific inhibition of COX-2
effectively reduced many parameters of UVB-mediated inflammation,
including edema, dermal neutrophil infiltration and activation, plasma
PGE2 levels and the formation of sunburn cells. By inhibiting this
inflammatory response, topical **celecoxib** treatment may
ultimately be effective in preventing UVB-induced tumor development in the
skin.
ST skin inflammation UV radiation **Celecoxib**
cyclooxygenase inhibitor; antiinflammatory **Celecoxib**
cyclooxygenase inhibitor skin UV radiation
IT Anti-inflammatory agents
Dermatitis
UV B radiation

(cyclooxygenase 2 inhibitor **Celecoxib** suppression of
 UVB-mediated cutaneous inflammation)

IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (for cyclooxygenase 2; cyclooxygenase 2 inhibitor **Celecoxib** suppression of UVB-mediated cutaneous inflammation)

IT 169590-42-5, **Celecoxib**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase 2 inhibitor **Celecoxib** suppression of
 UVB-mediated cutaneous inflammation)

IT 39391-18-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2, inhibitors; cyclooxygenase 2 inhibitor
Celecoxib suppression of UVB-mediated cutaneous inflammation)

RE.CNT 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Baba, T; J Derma Science 1996, V12, P18 MEDLINE
- (2) Bayerl, C; Photoderm Photoimmuo Photomed 1995, V11, P149 MEDLINE
- (3) Bennett, A; Gut 1987, V28, P315 CAPLUS
- (4) Bennett, A; Prog Lipid Res 1986, V25, P539 CAPLUS
- (5) Black, A; Br J Clin Pharmacol 1978, V5, P431 CAPLUS
- (6) Black, A; Br J Clin Pharmacol 1982, V13, P351 CAPLUS
- (7) Boyne, A; Anal Biochem 1972, V46, P639 CAPLUS
- (8) Brash, D; Trends Genet 1997, V13, P410 CAPLUS
- (9) Buckman, S; Carcinogenesis 1998, V19, P723 CAPLUS
- (10) Cohen, D; Photochem Photobiol 1993, V57, P383 CAPLUS
- (11) Eberlein-Konig, B; Br J Dermatol 1998, V139, P415 CAPLUS
- (12) Eling, T; Pharmacol Ther 1992, V3, P261
- (13) Elmets, C; Photochem Photobiol 1982, V6, P715
- (14) Fischer, S; Mol Carcinog 1999, V25, P231 CAPLUS
- (15) Fulton, A; Cancer Res 1984, V44, P2416 CAPLUS
- (16) Furstenberger, G; Carcinogenesis 1989, V10, P91 MEDLINE
- (17) Gallagher, R; Arch Dermatol 1995, V131, P157 MEDLINE
- (18) Giardello, F; Eur J Cancer 1995, V31A, P1071
- (19) Gierse, J; Biochem J 1999, V339, P607 CAPLUS
- (20) Goodwin, J; J Clin Immunol 1983, V3, P295 CAPLUS
- (21) Greaves, M; J Invest Dermatol 1970, V54, P365 CAPLUS
- (22) Gresham, A; Am J Physiol 1996, V270, PC1037 CAPLUS
- (23) Grewe, M; J Invest Dermatol 1993, V101, P528 CAPLUS
- (24) Hershman, H; Biochem Biophys Acta 1996, V1299, P125
- (25) Hla, T; Proc Natl Acad Sci USA 1992, V89, P7384 CAPLUS
- (26) Hruza, L; J Invest Dermatol 1993, V100, P35S CAPLUS
- (27) Jung, E; J Dermatol 1991, V18, P1 MEDLINE
- (28) Jung, T; Laryngoscope 1985, V95, P307 CAPLUS
- (29) Katiyar, S; Photochem Photobiol 1999, V69, P148 CAPLUS
- (30) Kripke, M; Immunol Rev 1984, V80, P87 MEDLINE
- (31) Kripke, M; J Dermatol 1991, V18, P429 MEDLINE
- (32) Kuwamoto, K; J Invest Dermatol 2000, V114, P241 CAPLUS
- (33) Ledwith, B; J Biol Chem 1997, V272, P3707 CAPLUS
- (34) Lupulescu, A; Prostaglandins, Leukotrienes and Ess Fatty Acids 1995, V54, P83
- (35) Maderazo, E; J Pharm Sci 1984, V73, P1403 CAPLUS
- (36) Maldve, R; Molec Carcinogen 1996, V17, P207 CAPLUS
- (37) Marks, R; Aust Paed J 1988, V24, P337 MEDLINE
- (38) Marks, R; Med J Aust 1990, V152, P62 MEDLINE
- (39) Marnett, L; Cancer Res 1992, V52, P5575 CAPLUS
- (40) Marshall, K; Am J Orthop 1999, V28, P19 MEDLINE
- (41) Mathur, G; J Invest Dermatol 1972, V58, P291 CAPLUS
- (42) McCormick, D; Br J Cancer 1983, V48, P859 CAPLUS

(43) Mehlisch, D; Clin Pharmacol Ther 1997, V61, P195
 (44) Muller-Decker, K; Mol Carcinog 1995, V12, P31 MEDLINE
 (45) Muller-Decker, K; Molec Carcinogen 1995, V12, P31 MEDLINE
 (46) Narisawa, T; Carcinogenesis 1993, V14, P1493
 (47) Oates, J; N Engl J Med 1988, V319, P689 MEDLINE
 (48) Oberyszyn, T; Mol Carcinog 1998, V22, P16 CAPLUS
 (49) Parrett, M; Int J Oncol 1997, V10, P503 CAPLUS
 (50) Patrono, C; Kidney Inst 1987, V32, P1 CAPLUS
 (51) Pentland, A; Carcinogenesis 1999, V20, P1939 CAPLUS
 (52) Pentland, A; J Clin Invest 1986, V77, P246 CAPLUS
 (53) Reddy, B; Cancer Res 1996, V56, P4566 CAPLUS
 (54) Reddy, B; Carcinogenesis 1993, V14, P1493 CAPLUS
 (55) Rigas, B; J Lab Clin Med 1993, V122, P518 MEDLINE
 (56) Ristimaki, A; J Biol Chem 1994, V269, P11769 CAPLUS
 (57) Rivas, J; J Leukoc Biol 1994, V56, P769 CAPLUS
 (58) Robertson, F; Cancer Lett 1998, V122, P165 CAPLUS
 (59) Sano, H; Cancer Res 1995, V55, P3785 CAPLUS
 (60) Savage, J; J Invest Dermatol 1993, V10, P532
 (61) Schwarz, T; Dermatologica 1985, V171, P450 CAPLUS
 (62) Seibert, K; Proc Natl Acad Sci USA 1994, V91, P12013 CAPLUS
 (63) Seibert, K; Proc Natl Acad Sci USA 1994, V91, P12013 CAPLUS
 (64) Simchowitz, L; Arthritis Rheum 1979, V22, P755 CAPLUS
 (65) Simon, L; Arthritis Rheum 1998, V41, P1591 CAPLUS
 (66) Smolen, J; Biochem Pharmacol 1980, V29, P533 CAPLUS
 (67) Snyder, D; J Invest Dermatol 1975, V64, P322 CAPLUS
 (68) Sontag, S; Drugs 1996, V32, P445
 (69) Soter, N; Semin Dermatol 1990, V9, P11 MEDLINE
 (70) Stern, M; Carcinogenesis 1998, V19, P125 CAPLUS
 (71) Trush, M; Food Chem Toxicol 1994, V32, P143 CAPLUS
 (72) Tsujii, M; Cell 1995, V83, P493 CAPLUS
 (73) Tsujii, M; Cell 1998, V93, P705 CAPLUS
 (74) Turner, R; J Rheumatol 1984, V11, P265 CAPLUS
 (75) Vane, J; Proc Natl Acad Sci USA 1994, V91, P2046 CAPLUS
 (76) Vile, G; Arch Biochem Biophys 1998, V359, P51 CAPLUS
 (77) Wahlberg, J; Contact Dermatitis 1993, V28, P141 MEDLINE
 (78) Wallace, J; Gastroenterol Clin North Am 1992, V21, PL631
 (79) Wu, K; J Lab Clin Med 1996, V128, P242 CAPLUS
 (80) Yamawaki, M; J Invest Dermatol 1997, V6, P716
 (81) Young, A; Photo-Dermat 1987, V4, P127 MEDLINE
 (82) Yuan, C; Cancer Res 2000, V60, P1084 CAPLUS

L200 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2000:72484 CAPLUS

DN 132:87911

TI Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison

AU Emery, Paul; Zeidler, Henning; Kvien, Tore K.; Guslandi, Mario; Naudin, Raphael; Stead, Helen; Verburg, Kenneth M.; Isakson, Peter C.; Hubbard, Richard C.; Geis, G. Steven

CS Department of Rheumatology and Rehabilitation, University of Leeds, Leeds, UK

SO Lancet (1999), 354(9196), 2106-2111

CODEN: LANCAO; ISSN: 0140-6736

PB Lancet Ltd.

DT Journal

LA English

CC 1-7 (Pharmacology)

AB Background: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX), which leads to suppression of COX-1-mediated prodn. of gastrointestinal-protective prostaglandins. Gastrointestinal injury is a common outcome. We compared the efficacy, safety, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX inhibitor. Methods: 655 patients with adult-onset rheumatoid arthritis of at least 6 mo' duration

were randomly assigned oral **celecoxib** 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 wk. Anti-inflammatory and analgesic activity and tolerability were assessed at baseline, every 4 wk, and at week 24. We assessed gastrointestinal safety by upper-gastrointestinal endoscopy within 7 days of the last treatment dose at centers where the procedure was available. Anal. was by intention-to-treat. Findings: 430 patients underwent endoscopy (**celecoxib** n=212, diclofenac n=218). The two drugs were similar in management of rheumatoid arthritis pain and inflammation. Gastroduodenal ulcers were detected endoscopically in 33 (15%) patients treated with diclofenac and in eight (4%) in the **celecoxib** group ($p<0.001$). The rate of withdrawal for any gastrointestinal-related adverse event, most commonly abdominal pain, diarrhea, and dyspepsia, was nearly three times higher in the diclofenac-treated group than in the **celecoxib** group (16 vs. 6%; $p<0.001$). Interpretation: **Celecoxib** showed sustained anti-inflammatory and analgesic activity similar to diclofenac, with a lower frequency of upper gastrointestinal ulceration or gastrointestinal adverse events, and tolerability was better.

ST **celecoxib** diclofenac rheumatoid arthritis stomach ulcer

IT Antirheumatic agents

Dyspepsia

Ulcer

(efficacy and safety of **celecoxib** vs. diclofenac in long-term management of rheumatoid arthritis in humans)

IT 15307-86-5, Diclofenac 169590-42-5, **Celecoxib**

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(efficacy and safety of **celecoxib** vs. diclofenac in long-term management of rheumatoid arthritis in humans)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) ARA Glossary Committee; Dictionary of the Rheumatic Disease 1988, V1
- (2) Agrawal, N; Dig Dis Sci 1995, V40, P1125 MEDLINE
- (3) Akdamar, K; Gastrointest Endoscopy 1986, V32, P78 MEDLINE
- (4) Arnett, F; Arthritis Rheum 1988, V31, P315 MEDLINE
- (5) Barrier, C; Arthritis Rheum 1989, V32, P926 MEDLINE
- (6) Cooperating Clinics Committee of American Rheumatism Association; Arthritis Rheum 1965, V8, P302
- (7) Crofford, L; J Clin Invest 1994, V93, P1095 CAPLUS
- (8) Felson, D; Arthritis Rheum 1995, V38, P727 MEDLINE
- (9) Gabriel, S; Ann Intern Med 1991, V115, P787 MEDLINE
- (10) Gierse, J; Biochem J 1995, V305, P479 CAPLUS
- (11) Ihmaki, T; Scand J Gastroenterol 1979, V14, P801
- (12) Kargman, S; Am Gastroenterol Assoc 1996, V111, P445 CAPLUS
- (13) Kirwan, J; Br J Rheumatol 1986, V25, P206 MEDLINE
- (14) Kolodny, A; J Rheumatol 1988, V15, P1205 MEDLINE
- (15) Kujubu, D; J Biol Chem 1991, V266, P12866 CAPLUS
- (16) Laneuville, O; J Pharmacol Exp Ther 1994, V271, P927 CAPLUS
- (17) Langman, M; Lancet 1994, V343, P1075 MEDLINE
- (18) Masferrer, J; Proc Natl Acad Sci USA 1994, V91, P3228 CAPLUS
- (19) Needleman, P; Ann Rev Biochem 1986, V55, P69 CAPLUS
- (20) Penning, T; J Med Chem 1997, V40, P1347 CAPLUS
- (21) Roth, S; Clin Drug Invest 1995, V9, P171
- (22) Sano, H; J Clin Invest 1992, V89, P97 CAPLUS
- (23) Seibert, K; Proc Natl Acad Sci USA 1994, V91, P12013 CAPLUS
- (24) Silverstein, F; Ann Intern Med 1995, V123, P241 MEDLINE
- (25) Simon, L; Arthritis Rheum 1998, V41, P1591 CAPLUS
- (26) Singh, G; J Rheumatol 1998, V25(suppl 51), P8
- (27) Smith, W; Adv Immunol 1996, V62, P167 CAPLUS
- (28) Steinbrocker, O; JAMA 1949, V140, P659
- (29) Vane, J; Nat New Biol 1971, V231, P232 CAPLUS
- (30) Vane, J; Proc Natl Acad Sci USA 1994, V91, P2046 CAPLUS

(31) Ward, J; *Arthritis Rheum* 1983, V26, P1303 MEDLINE
(32) Xie, W; *Proc Natl Acad Sci USA* 1991, V88, P2692 CAPLUS

L200 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1999:669180 CAPLUS
DN 132:160652
TI **Celecoxib**, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis
AU Goldenberg, Marvin M.
CS Mount Sinai NYU Health, New York, NY, USA
SO Clinical Therapeutics (1999), 21(9), 1497-1513
CODEN: CLTHDG; ISSN: 0149-2918
PB Excerpta Medica
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review with 56 refs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed drugs, despite their well-established assocn. with gastroduodenal injury. Recent discovery of the cyclooxygenase (COX) isoenzymes COX-1 and COX-2 has improved our knowledge of the action of NSAIDs. COX-1 is continuously expressed in almost all tissues, where it converts arachidonate to the prostaglandins (PGs) important in homeostatic function; COX-2 is present in immune cells, blood vessel endothelial cells, and synovial fibroblasts. Classic NSAIDs inhibit both COX isoenzymes by occupying the cyclooxygenase-active site, preventing access by arachidonic acid. In theory, a drug such as **celecoxib** that selectively inhibited COX-2 might block inflammation, pain, and fever while reducing the side effects (gastric erosions and ulcers) assocd. with inhibition of COX-1. In animal models of inflammation and pain, **celecoxib** has shown marked suppression of PG prodn. and inflammation compared with indomethacin, the std. COX-1/COX-2 inhibitor. In clin. trials, **celecoxib** dosed at 100, 200, and 400 mg BID was found to significantly reduce the signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis. In one RA study, **celecoxib** was found to be as clin. effective as diclofenac after 24 wk of **treatment**; at the end of the study, gastroduodenal ulcers occurred significantly more frequently in the diclofenac group (15%) than in the **celecoxib** group (4%). In a 1-wk endoscopy study comparing **celecoxib** with naproxen and placebo, the incidence of gastric erosions/ulcers was significantly greater in the naproxen group than in the **celecoxib** or placebo group. The most common adverse effects of **celecoxib** in clin. studies were headache, **diarrhea**, abdominal discomfort, and dizziness. **Celecoxib** has shown significant equiv. anti-inflammatory and analgesic efficacy and has produced less endoscopically apparent gastrointestinal (GI) ulceration or erosion than have 3 classic NSAIDs. Whether it will have long-term GI adverse effects or interact with other medications to cause serious adverse responses (eg, increased GI bleeding or rash in conjunction with other sulfonamide-like drugs) is unknown and remains to be established.
ST review COX2 inhibitor **celecoxib** rheumatoid arthritis
osteoarthritis
IT Analgesics
Antiarthritics
Antirheumatic agents
 (COX-2 inhibitor **celecoxib** for rheumatoid arthritis and
 osteoarthritis **treatment**)
IT Prostaglandins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (COX-2 inhibitor **celecoxib** for rheumatoid arthritis and
 osteoarthritis **treatment**)
IT Anti-inflammatory agents
 (nonsteroidal; COX-2 inhibitor **celecoxib** for rheumatoid

arthritis and osteoarthritis treatment)
IT Digestive tract
(toxicity; COX-2 inhibitor celecoxib for rheumatoid arthritis and osteoarthritis treatment)
IT Stomach, disease
(ulcer; COX-2 inhibitor celecoxib for rheumatoid arthritis and osteoarthritis treatment)
IT 169590-42-5, Celecoxib
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(COX-2 inhibitor celecoxib for rheumatoid arthritis and osteoarthritis treatment)
IT 39391-18-9, Cyclooxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COX-2 inhibitor celecoxib for rheumatoid arthritis and osteoarthritis treatment)
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anderson, G; J Clin Invest 1996, V97, P2672 CAPLUS
(2) Anon; FDC Reports 1998, V60, P3
(3) Appelby, S; Biochem J 1994, V302, P723
(4) Brooks, P; N Engl J Med 1991, V324, P1716 MEDLINE
(5) Crofford, L; J Clin Invest 1994, V93, P1095 CAPLUS
(6) Crofford, L; J Rheumatol 1997, V24(Suppl 49), P15
(7) Cronstein, B; Annu Rev Pharmacol Toxicol 1995, V35, P449 CAPLUS
(8) De Witt, D; Arch Biochem Biophys 1993, V306, P94 CAPLUS
(9) Eberhart, C; Gastroenterology 1995, V109, P285 CAPLUS
(10) Flower, R; Pharmacol Rev 1974, V26, P33 CAPLUS
(11) Fries, J; Gastroenterology 1989, V96, P647 MEDLINE
(12) Fu, J; J Biol Chem 1990, V265, P16737 CAPLUS
(13) GD Searle & Co; Celebrex [package insert] 1999
(14) Geis, G; Arthritis Rheum 1998, V41(Suppl 9), PS316
(15) Gierse, J; Biochem J 1995, V305, P479 CAPLUS
(16) Hawkey, C; Lancet 1999, V353, P307 CAPLUS
(17) Hoff, T; FEBS Lett 1993, V320, P38 CAPLUS
(18) Hubbard, R; Arthritis Rheum 1996, V39(Suppl 9), PS226
(19) Hubbard, R; Arthritis Rheum 1997, V40(Suppl 9), PS51
(20) Hubbard, R; J Invest Med 1996, V44, P293
(21) Jones, D; J Biol Chem 1993, V268, P9049 CAPLUS
(22) Karim, A; Arthritis Rheum 1998, V41(Suppl 9), PS315
(23) Kosaka, T; Eur J Biochem 1994, V221, P889 CAPLUS
(24) Kujubu, D; J Biol Chem 1991, V266, P12866 CAPLUS
(25) Kurumbail, R; Nature 1996, V384, P644 CAPLUS
(26) Laneuville, O; J Pharmacol Exp Ther 1994, V271, P927 CAPLUS
(27) Lanza, F; Am J Gastroenterol 1993, V88, P1318 MEDLINE
(28) Lanza, F; Arthritis Rheum 1997, V40(Suppl 9), PS93
(29) Lee, S; J Biol Chem 1992, V267, P25934 CAPLUS
(30) Marnett, L; Cancer Res 1992, V52, P5575 CAPLUS
(31) Masferrer, J; Proc Natl Acad Sci USA 1992, V89, P3917 CAPLUS
(32) Masferrer, J; Proc Natl Acad Sci USA 1994, V91, P3228 CAPLUS
(33) McAdam, B; Proc Natl Acad Sci USA 1999, V96, P272 CAPLUS
(34) Mengle-Gaw, L; Arthritis Rheum 1997, V40(Suppl 9), PS88
(35) Needleman, P; Sci Med 1998, V1, P35
(36) O'Banion, M; J Biol Chem 1991, V266, P23261 CAPLUS
(37) O'Neill, G; Mol Pharmacol 1994, V45, P245 CAPLUS
(38) Penning, T; J Med Chem 1997, V40, P1347 CAPLUS
(39) Picot, D; Nature 1994, V367, P243 CAPLUS
(40) Raz, A; Proc Natl Acad Sci USA 1989, V86, P1657 CAPLUS
(41) Ristimaki, A; J Biol Chem 1994, V269, P11769 CAPLUS
(42) Roth, G; Proc Natl Acad Sci USA 1975, V72, P3073 CAPLUS
(43) Roth, S; Arch Intern Med 1996, V156, P1623 CAPLUS
(44) Sano, H; J Clin Invest 1992, V89, P97 CAPLUS
(45) Siebert, K; Proc Natl Acad Sci USA 1994, V91, P12013

(46) Simon, L; Arthritis Rheum 1998, V41, P1591 CAPLUS
 (47) Smith, W; Biochim Biophys Acta 1991, V1083, P1 CAPLUS
 (48) Smith, W; Immunology 1996, V62, P167 CAPLUS
 (49) Smith, W; Nature 1971, V231, P235
 (50) The Cooperating Clinics Committee of the American Rheumatism Association; Arthritis Rheum 1965, V8, P302
 (51) Vane, J; Br J Rheumatol 1996, V35(Suppl 1), P1
 (52) Vane, J; Nature 1971, V231, P232 CAPLUS
 (53) Vane, J; Proc Natl Acad Sci USA 1994, V91, P2046 CAPLUS
 (54) Whelton, A; J Clin Pharmacol 1991, V31, P588 MEDLINE
 (55) Xie, W; Proc Natl Acad Sci USA 1991, V88, P2692 CAPLUS
 (56) Zhao, S; Arthritis Rheum 1997, V40(Suppl 9), PS88

L200 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1997:562995 CAPLUS

DN 127:225303

TI Immunosuppressive combinations containing a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

IN Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary

PA G.D. Searle & Co., USA; Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K045-06

CC 63-6 (Pharmaceuticals)


Section cross-reference(s): 28

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9729774	A1	19970821	WO 1997-US1421	19970211
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2246336	AA	19970821	CA 1997-2246336	19970211
	AU 9719525	A1	19970902	AU 1997-19525	19970211
	EP 880363	A1	19981202	EP 1997-907545	19970211
	EP 880363	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001506574	T2	20010522	JP 1997-529358	19970211
	AT 223732	E	20020915	AT 1997-907545	19970211
	ES 2183140	T3	20030316	ES 1997-907545	19970211
	US 6407140	B1	20020618	US 2000-489311	20000121
	US 2003004191	A1	20030102	US 2002-137231	20020502
PRAI	US 1996-600655	A1	19960213		
	WO 1997-US1421	W	19970211		
	US 2000-489311	A3	20000121		

OS MARPAT 127:225303

GI



AB Immunosuppressant compns. contg. a combination of a cyclooxygenase-2 inhibitor (which inhibits conversion of arachidonic acid to prostaglandins) and a LTA4 hydrolase inhibitor are useful in reducing recipient rejection of transplanted organs and for **treatment** of autoimmune diseases. Thus, F2CHCO2Et reacted with 3-fluoro-4-methoxyacetophenone to form 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione, which was condensed with 4-sulfonamidophenylhydrazine-HCl to produce the cyclooxygenase-2 inhibitor I. A formulation was prep'd. contg. 350 mg I and 700 mg 3-[N-methyl-N-[3-[(4-phenylmethyl)phenoxy]propyl]amino]propanoic acid (LTA4 hydrolase inhibitor).

ST immuno^suppressant cyclooxygenase inhibitor; leukotriene hydrolase inhibitor transplant rejection

IT Kidney, disease
(Goodpasture's syndrome; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Thyroid gland, disease
(autoimmune thyroiditis; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT **Dermatitis**
(contact; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Allergy inhibitors
Allergy inhibitors
(delayed hypersensitivity; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Respiratory tract
(disease, hypersensitivity; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Kidney, disease
(glomerulonephritis; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Transplant and Transplantation
(graft-vs.-host reaction; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Anemia (disease)
(hemolytic, autoimmune; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Allergy
(hypersensitivity, respiratory tract; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Addison's disease
(idiopathic; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Allergy
(immediate hypersensitivity; immuno^suppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics

Autoimmune disease
 Encephalomyelitis
 Graves' disease
 Immunosuppressants
 Meningitis
 Myasthenia gravis
 Sjogren's syndrome
 Transplant rejection
 Urticaria
 (immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and
 LTA4 hydrolase inhibitor)
 IT Granuloma
 (inhibitors; immunosuppressive combinations contg. cyclooxygenase-2
 inhibitor and LTA4 hydrolase inhibitor)
 IT Connective tissue
 (mixed connective tissue disease; immunosuppressive combinations contg.
 cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)
 IT Lung, disease
 (pneumonitis, hypersensitive; immunosuppressive combinations contg.
 cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)
 IT Shock (circulatory collapse)
 (septic; immunosuppressive combinations contg. cyclooxygenase-2
 inhibitor and LTA4 hydrolase inhibitor)
 IT Platelet (blood)
 (thrombocytopenia; immunosuppressive combinations contg.
 cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)
 IT Purpura (disease)
 (thrombocytopenic, autoimmune; immunosuppressive combinations contg.
 cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)
 IT Thyroid gland, disease
 Thyroid gland, disease
 (thyroiditis; immunosuppressive combinations contg. cyclooxygenase-2
 inhibitor and LTA4 hydrolase inhibitor)
 IT 39391-18-9
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2, inhibitors; immunosuppressive combinations contg. cyclooxygenase-2
 inhibitor and LTA4 hydrolase inhibitor)
 IT 142259-95-8, RP-64966 179021-09-1 179021-10-4 179022-08-3
 186901-93-9 186901-94-0 186901-95-1 186901-96-2 186901-97-3
 186901-98-4 194997-63-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (LTA4 hydrolase inhibitor; immunosuppressive combinations contg.
 cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)
 IT 71125-38-7, Meloxicam 80937-31-1, Flosulide 88149-94-4, DuP 697
 123653-11-2, NS-398 162011-83-8 169590-41-4 **169590-42-5**
 170569-86-5 177660-77-4 177660-80-9 177660-88-7 181695-76-1
 185344-61-0 194997-65-4 194997-66-5 194997-67-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (cyclooxygenase-2 inhibitor; immunosuppressive combinations contg.
 cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)
 IT 162011-90-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and
 LTA4 hydrolase inhibitor)
 IT 99-91-2 321-28-8, 2-Fluoroanisole 383-63-1, Ethyl trifluoroacetate
 454-31-9, Ethyl difluoroacetate 27918-19-0, 4-Sulfonamidophenylhydrazine
 hydrochloride
 RL: RCT (Reactant); RACT (Reactant or reagent)

(immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and
 LTA4 hydrolase inhibitor)
 IT 455-91-4P 18931-60-7P 170570-77-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and
 LTA4 hydrolase inhibitor)
 IT 90119-07-6, Leukotriene A4 hydrolase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; immuno-suppressive combinations contg. cyclooxygenase-2
 inhibitor and LTA4 hydrolase inhibitor)

L200 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:557660 CAPLUS
 DN 127:239120
 TI Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene B4
 receptor antagonist for reducing transplant rejection
 IN Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary
 PA G.D. Searle & Co., USA; Gregory, Susan A.; Isakson, Peter C.; Anderson,
 Gary
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K045-06
 ICS A61K031-00; A61K031-10; A61K031-18; A61K038-13
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1, 2
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9729775	A1	19970821	WO 1997-US1422	19970211
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2246356	AA	19970821	CA 1997-2246356	19970211
	AU 9722500	A1	19970902	AU 1997-22500	19970211
	EP 880362	A1	19981202	EP 1997-905663	19970211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000505445	T2	20000509	JP 1997-529359	19970211
	US 6172096	B1	20010109	US 1998-75633	19980511
PRAI	US 1996-600580	A1	19960213		
	WO 1997-US1422	W	19970211		
OS	MARPAT	127:239120			
AB	Treatment with a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.				
ST	immunodepressant transplant cyclooxygenase2 inhibitor leukotrieneB4 antagonist				
IT	Kidney, disease (Goodpasture's syndrome; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)				
IT	Leukocyte (activation of, inhibitors of; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)				
IT	Anti-inflammatory agents				

Autoimmune disease
Encephalomyelitis
Granuloma
Immunosuppressants
Meningitis
Urticaria
(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Myasthenia gravis
Sjogren's syndrome
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Dermatitis
(contact; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Drug delivery systems
(emulsions; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Kidney, disease
(glomerulonephritis; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Transplant and Transplantation
(graft-vs.-host reaction; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Anemia (disease)
(hemolytic; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Lung, disease
(hypersensitivity pneumonitis; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Addison's disease
(idiopathic; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Leukotriene receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leukotriene B4, antagonists; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Drug delivery systems
(oral; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Shock (circulatory collapse)
(septic; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Purpura (disease)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thrombocytopenic, autoimmune; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT Thyroid gland, disease
Thyroid gland, disease
(thyroiditis; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT 39391-18-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, antagonists; compns. comprising a cyclooxygenase-2 inhibitor and a

leukotriene B4 receptor antagonist for reducing transplant rejection)
IT 127378-46-5, CI 987
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CI 987; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT 170569-86-5P 195061-35-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT 32222-06-3, Calcitriol 59865-13-3, Cyclosporin a 60940-34-3, Ebselen 71125-38-7, Meloxicam 79217-60-0, Cyclosporin 80937-31-1, Flosulide 85259-71-8, BAY 0-8276 88149-94-4, Dup 697 93014-16-5 101910-24-1, PF-5901 110501-66-1, TMK-688 111908-95-3, SK&F-104493 117423-74-2, LY 223982 117423-95-7, LY 213024 117690-79-6, LY-255283 118414-82-7, MK-886 119261-58-4, TEI 1338 120072-59-5, SC-41930 123653-11-2, NS-398 128253-31-6, Bay-x-1005 130211-75-5, T-757 132734-43-1, LY 233569 133430-69-0, ETH-615 134578-96-4, ONO LB457 135199-82-5, LY 264086 135893-33-3, PF 10042 136326-31-3, WAY 121006 141059-52-1, SC-51146 141748-00-7, RP 69698 141835-49-6, RG 14893 142422-79-5, RP 66153 146461-98-5, SM 15178 147030-01-1, MK-591 147398-01-4, CGS-25019C 147432-77-7, Ontazolast 150399-22-7, SB-201993 153034-77-6, LY 292728 153633-01-3, SC-53228 154413-61-3, SB-209247 158081-99-3, Pfizer 105696 161172-51-6, LY-293111 162011-83-8
162011-90-7 162153-46-0, SC 52798 169590-41-4
169590-42-5 177660-77-4 177660-80-9 177660-92-3
180208-37-1, SB-201146 181695-72-7 185344-51-8 185344-55-2
186912-85-6, ONO-LB-448 186912-92-5, RP 66364 186912-94-7, SC-50505
195061-34-8 195215-25-9, BPC 15 195215-47-5, MNX 160 195215-53-3, S 2474 195215-55-5, SR 2566
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT 99-91-2, 4'-Chloroacetophenone 383-63-1, Ethyl trifluoroacetate 454-31-9, Ethyl difluoroacetate 27918-19-0, 4-Sulfonamidophenyl hydrazine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT 455-91-4P, 3'-Fluoro-4'-methoxyacetophenone 18931-60-7P 170570-77-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

L200 ANSWER 5 OF 36 USPATFULL

AB The present invention provides methods for **treating** intestinal fluid loss, whooping cough, anthrax, and conditions associated with smooth muscle contraction. The present invention also provides methods for inhibiting adenylyl cyclase in vivo and in vitro.

SUMM [0003] Diarrheal diseases in humans and non-human animals can be caused by several types of pathogens, including viruses, bacteria, parasites, and rotaviruses. The most prevalent are the bacteria Escherichia coli and Vibrio cholerae. Diarrheal diseases are a prevalent cause of morbidity and mortality in less developed countries. These diseases also afflict populations in developed countries. For example, each year in the US over 200,000 children 5 years and younger are hospitalized with acute diarrheal diseases. The infectious **diarrheas** are the leading cause of morbidity and mortality worldwide a common class of illness in the United States.

SUMM [0004] Due to its many causes, acute infectious **diarrhea** can occur more than once in the same person, and, therefore, it is unlike most chronic conditions which typically occur once. Unlike other digestive diseases, infectious **diarrheas** are communicable via person-to-person contact or through contaminated food or water and can spread endemically or in epidemics through households, schools, day-care centers, nursing homes, and communities. Diarrheal diseases also pose a serious challenge in the raising of non-human animals in the farming industry, particularly with young calves and pigs.

SUMM [0005] The present invention represents an advance in the art of **treating** intestinal fluid loss in a subject. The invention provides methods for **treating** intestinal fluid loss in a subject. The method includes administering to a subject who has or is at risk of developing intestinal fluid loss a composition that includes an effective amount of heterocycle-containing compounds such as a heterocycle derivative, for instance a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. In some embodiments of this aspect of the invention the fluid loss is not associated with a pathogen polypeptide having ADP-ribosylation activity, and in other aspects the intestinal fluid loss is associated with a pathogen polypeptide having ADP-ribosylation activity.

SUMM [0008] The present invention further provides a method for **treating** whooping cough in a subject, including administering to a subject who has or is at risk of developing whooping cough a composition that includes an effective amount of a heterocycle-containing compound.

SUMM [0009] The present invention also provides a method for **treating** anthrax in a subject, including administering to a subject who has or is at risk of developing anthrax a composition that includes an effective amount of a heterocycle-containing compound.

DRWD [0021] FIG. 11. **Celecoxib** reduced CT-induced fluid accumulation in murine intestinal loops. CT, cholera toxin; CT + **celecoxib** in loop, mice challenged with cholera toxin and two 80 microgram (mg) doses of **celecoxib** (one injected into the intestinal lumen at the time of challenge with CT, the second injected intraperitoneally two hours later); CT +**celecoxib** IP only, mice challenged with cholera toxin and two 80 microgram (.mu.g) doses of **celecoxib** (one injected intraperitoneally at the time of challenge with CT, the second injected intraperitoneally two hours later). The vertical bars indicate one standard error above or below the mean. The asterisks indicate a significant difference from the positive control group as determined by the Tukey test (P<0.05).

DRWD [0022] FIG. 12. Effect of imidazole (2.7 mmoles), PGE sub.2-Histidine

adduct (52 .mu.moles) and **celecoxib** (0.52 mmoles) on the enzyme Adenylate Cyclase (4.6 nmoles). Blank has no enzyme and inhibitors, while Enzyme (E) has only enzyme and no inhibitors. Enzyme containing specific inhibitors are represented as E+imidazole, E+PGE.sub.2-Histidine and E+**celecoxib**. Significant difference from the control value (E) is indicated by *P.ltoreq.0.05 and *P.ltoreq.0.001 as determined by Student's t-test.

DRWD [0023] FIG. 13. Fluid accumulation in Cholera toxin challenged murine intestinal ligated loops **treated** with the COX-1 inhibitor SC-560. n, number of animals; CT 1 .mu.g/loop, 1 microgram of cholera toxin added to each loop; CT +9 nM SC-560, 1 microgram of cholera toxin and 9 nanomolar SC-560 added to each loop The asterisks indicate a significant difference from the positive control (CT) as determined by the Tukey test.

DRWD [0025] FIG. 15. IC.sub.50 of **celecoxib** for adenylate cyclase.

DETD [0039] **rofecoxib** (available under the trade designation **VIOXX**, from Merck & Co., Whitehouse Station, N.Y.), which has the following structure: ##STR9##

DETD [0040] **celecoxib** (available under the trade designation **CELEBREX**, from Searle and Co., Skokie, Ill.), which has the following structure: ##STR10##

DETD [0049] Typically, the compositions of the invention will be administered from about 1 to about 5 times per day. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the subject **treated** and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound. The amount of heterocycle-containing compound in such therapeutically useful compositions is such that the dosage level will be effective to prevent or suppress the condition the subject has or is at risk for.

DETD [0055] The present invention is further directed to methods for **treating** certain conditions in a subject as well as various *in vitro* methods. The conditions include, for instance, intestinal fluid loss, whooping cough, anthrax, and smooth muscle contraction, and are described in greater detail herein. The methods include administering a composition including a heterocycle-containing compound to a subject who is at risk of developing or has developed one of the conditions. As used herein, the term "subject" includes humans, agriculturally important animals such as cows, pigs, poultry, sheep, and horses, as well as other animals (for instance, mice, rats, dogs, cats, and rabbits) that can be used as animal models in the study of the conditions described herein.

DETD [0056] **Treatment** of the conditions described herein can be prophylactic or, alternatively, can be initiated after the development of a condition described herein. **Treatment** that is prophylactic, for instance, initiated before a subject manifests symptoms of a condition described herein and/or before exposure to a pathogen associated with (i.e., caused by) one of the conditions described herein, is referred to herein as **treatment** of a subject that is "at risk" of developing the condition. Accordingly, administration of a composition can be performed before, during, or after the occurrence of the conditions described herein.

Treatment initiated after the development of a condition may result in decreasing the severity of the symptoms of one of the conditions, or completely removing the symptoms. Non-limiting examples of subjects particularly suited to receiving the composition are those undergoing antibiotic **treatment**, in particular the elderly and the very young, preferably antibiotic **treatment** that has been associated with antibiotic-associated colitis, those traveling to a location where pathogens causing intestinal fluid loss are endemic (for instance, those likely to contract Traveler's **diarrhea**), and those infected with HIV.

DETD [0057] A composition that is administered to a subject who has or is at risk of developing a condition described herein includes an effective

amount of a heterocycle-containing compound, preferably, a heterocycle derivative, and for certain embodiments, a diphenyl-substituted heterocycle derivative and/or a prostaglandin analog. As used herein, an "effective amount" is an amount effective to decrease or prevent (for prophylactic treatment) in a subject the symptoms associated with a condition described herein.

DETD [0058] An aspect of the invention is directed to a method of treating intestinal fluid loss in a subject. As used herein, the term "intestinal fluid loss" refers to various types of **diarrheas** (i.e., an increased frequency and/or liquidity of fecal discharges when compared to normal individuals with formed stools). Intestinal fluid loss can result from, for instance, increased fluid secretion (e.g., water and/or electrolytes) from intestinal cells into the intestinal lumen, decreased absorption of water and/or electrolytes from the intestinal lumen, and/or movement of blood and mucus into the intestinal lumen. Intestinal fluid loss is usually associated with the presence of a pathogen, although foods having hyperosmolality can elicit hypersecretion of water and electrolytes. This is in contrast to idiopathic inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. The latter chronic diseases are not associated with any particular infectious agent and result from uncontrolled inflammation of the colon and other regions of the intestinal tract.

DETD [0059] Pathogens that cause intestinal fluid loss include pathogens that are present in the intestinal lumen (for instance, *Vibrio cholerae*) or present in intestinal cells (for instance, *Shigella*), and pathogens that may not be present in the intestinal lumen or in intestinal cells (for instance, HIV). Examples of pathogens include viruses, parasites, and bacteria (see, for instance, Cotran et al., *Robbins Pathologic Basis of Disease*, 5.sup.th ed., W.B. Sanders Co., Philadelphia, pp. 328-335 (1994)). Intestinal fluid loss caused by pathogens is referred to in the art in numerous ways, including, for instance, **diarrhea**, **dysentery**, **Travelers' diarrhea**, and **scours** (in calves).

DETD [0066] In some aspects of the invention, when the intestinal fluid loss is not associated with a pathogen polypeptide having ADP-ribosylation activity (e.g., the intestinal fluid loss is associated with antibiotic treatment, the age of the subject, and/or infection by, for instance, a virus, a bacterium, a parasite, or a combination thereof), the heterocycle-containing compound present in the composition is a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. Examples of diphenyl heterocycles that can be used in this aspect of the invention include **celecoxib**, **rofecoxib**, SC-560, and DuP-697. Examples of prostaglandin analogs that can be used in this aspect of the invention include PGE₂-histidine and PGE₂-imidazole. Optionally, the composition can include, in addition to these heterocycle derivatives, an effective amount of metronidazole (available under the trade designation FLAGYL, from Searle and Co.) and/or an effective amount of indomethacin (available under the trade designation INDOCIN, from Merck & Co.). Of these two, metronidazole is preferred.

DETD [0067] In another aspect of the invention, when the intestinal fluid loss is associated with a pathogen polypeptide having ADP-ribosylation activity (e.g., the intestinal fluid loss is associated with *V. cholerae*, ETEC, or a combination thereof), the heterocycle-containing compound present in the composition is preferably an unsubstituted heterocyclic compound (e.g., imidazole), a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. More preferably, the heterocycle-containing compound present in the composition can be an unsubstituted heterocyclic compound (e.g., imidazole), a diphenyl heterocycle derivative, or a combination thereof. Examples of diphenyl heterocycles that can be used in this aspect of the invention include **rofecoxib**, SC-560, DuP-697, and in some embodiments, **celecoxib**. Preferably, the compositions do not include **celecoxib** for this method. Examples of a prostaglandin

analog that can be used in some embodiments of this aspect of the invention include PGE₂-imidazole and PGE₂-histidine. Compositions useful in this method can include an effective amount of metronidazole and/or an effective amount of indomethacin. Of these two, metronidazole is preferred.

DETD [0068] The invention is further directed to a method of **treating** whooping cough in a subject. Whooping cough is a disease of the respiratory tract caused by *Bordetella pertussis*. After exposure to *B. pertussis*, cells of the respiratory tract have increased cAMP levels. The method includes administering to a subject who has or is at risk of developing whooping cough a composition that includes an effective amount of a heterocycle-containing compound. The heterocycle-containing compound present in the composition is preferably an unsubstituted heterocyclic compound (e.g., imidazole), a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. The heterocycle-containing compound present in the composition is more preferably a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. Optionally, the composition can include, in addition to, these preferred heterocycle derivatives, an effective amount of metronidazole and/or indomethacin. Of these two, metronidazole is preferred.

DETD [0069] Another aspect of the invention is directed to a method for **treating** anthrax in a subject. Anthrax is an often fatal disease caused by *Bacillus anthracis*. One factor expressed by *B. anthracis* that is important in causing disease is edema factor, an adenylate cyclase which causes tissue edema by increasing cAMP levels. The method includes administering to a subject who has or is at risk of developing anthrax a composition comprising an effective amount of a heterocycle-containing compound. The heterocycle-containing compound present in the composition is preferably an unsubstituted heterocyclic compound (e.g., imidazole), a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. The heterocycle-containing compound present in the composition is more preferably a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. The heterocycle-containing compound present in the composition is more preferably a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. Optionally, the composition can include, in addition to, these preferred heterocycle derivatives, an effective amount of metronidazole and/or indomethacin. Of these two, metronidazole is preferred.

DETD [0072] The method for inhibiting adenylate cyclase *in vivo* includes contacting a cell that has been removed from a subject or is in a subject with a composition that includes an amount of a heterocycle derivative effective to inhibit the generation of cAMP from ATP. The cell includes adenylate cyclase and a pathogen polypeptide having ADP-ribosylation activity. Several conditions are associated with excessive adenylate cyclase activity and include, for instance, intestinal fluid loss as in diarrheal disease, tracheal and bronchial edema as in whooping cough, and pulmonary, gastrointestinal, and disseminated edema as in anthrax. Such conditions are described herein. The methods to inhibit adenylate cyclase can be used to **treat** such conditions.

DETD [0075] For methods of inhibiting adenylate cyclase, the heterocycle-containing compound present in the composition is preferably an unsubstituted heterocyclic compound (e.g., imidazole), a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof. More preferably, the heterocycle-containing compound present in the composition can be an unsubstituted heterocyclic compound (e.g., imidazole), a diphenyl heterocycle derivative, or a combination thereof. Examples of diphenyl heterocycles that can be used in this aspect of the invention include **rofecoxib**, SC-560, DuP-697, and in some embodiments, **celecoxib**. Preferably, methods for inhibiting adenylate cyclase include **celecoxib** and DuP-697. Compositions useful in this method can include an effective amount of metronidazole

SUMM There are drugs that can be helpful in controlling Crohn's disease, but at present there is no cure. **Treatment** is aimed at correcting nutritional deficiencies, controlling inflammation, relieving the symptoms of abdominal pain, **diarrhea**, and **rectal bleeding**. Drugs known to be used for this condition can help, but side effects can be deleterious. Surgeries that may be performed to alleviate symptoms include the removal of inflamed areas, draining of abscesses, and bowel resection.

SUMM *Mycobacterium paratuberculosis* is an obligate pathogen; that is, it cannot multiply outside the cells of animals. It is known to be present in a wide variety of animals, including primates and humans. The best-studied animal paratuberculosis is bovine Johne's disease (BJD), a disease that causes chronic **diarrhea**, weight loss, and malnutrition in cattle and affects up to 25% of the dairy cattle in the United States. Cows infected with BJD are known to secrete *Mycobacterium paratuberculosis* in their milk, which is not destroyed by standard milk pasteurization methods, but only by ultrapasteurization. This bacterium has also been cultured from a municipal water supply in the United States.

SUMM A further object is to provide a composition and method for **treating** patients shown by the screening method to be infected with *Mycobacterium paratuberculosis*.

SUMM These objects and others are attained by the present invention, a composition and associated methods for detecting and **treating** a *M. para.* infection such as Crohn's disease in a human and for predicting a genetic predisposition thereto.

SUMM An embodiment of the **treatment** composition of the present invention comprises at least one antibiotic effective in the eradication of *M. paratuberculosis*.

SUMM In an embodiment of the **treatment** method, the effective antibiotic is administered to a patient having been found positive for *M. paratuberculosis* by the serologic method of the invention.

DETD The data also support an improved serologic kit comprising the composition of the invention to provide earlier diagnosis and better **treatment** of Crohn's disease.

DETD With the indication that Crohn's disease is at least in part caused by the presence of *M. paratuberculosis*, a **treatment** regimen including an administration of antituberculosis drugs was proposed. However, this bacterium is known to be resistant to most of these drugs. An in vitro study was performed to evaluate seven anti-TB drugs against *M. para.* isolated from resected tissue of CD patients using the Bactec system, which is known in the art, and the results are given in Table 2.

DETD Twenty-nine CD patients who tested serologically positive for *M. para.* were selected for rifabutin and macrolide antibiotic therapy (RMAT) for a duration of 6 months to 1 year based upon their overall response to the **treatment**. The regimen included 250 mgm po bid clarithromycin, 150 mgm 1 po bid rifabutin, and 200 mgm po qd of a probiotic containing equal amounts of *Lactobacillus acidophilus* and *Lactobacillus rhamnosus*.

DETD After 3 months all the patients were assessed to determine overall response to the **treatment**. 28% (8/29) of the patients achieved a state of clinical remission (as defined by the CDAI criteria with a score <150) while being off all other medications. The majority of these patients had acute presentation of CD when placed on RMAT. 31% (9/29) of the patients were not in clinical remission but experienced significant improvements as they discontinued the use of all other Crohn's medications. 28% (8/29) of the patients noticed some improvements on

RMAT but were still using traditional medications, such as sulfasalazine and corticosteroids. 14% (4/29) were nonresponders, since they were unable to tolerate the RMAT medications and discontinued therapy. These findings support the use of RMAT in the **treatment** of CD.

DETD The patient demonstrated significant healing (80%) of an ulcer seen in the ileum by endoscopy following a regimen of 250 mg clarithromycin twice a day and 150 mg rifabutin daily. The patient became asymptomatic in 2 weeks, and a followup endoscopy was performed after completing 1 month of **treatment**. The 4-cm ulcer had reduced in size to 1 cm, with excellent reepithelialization from the edge of the ulcer inward. The remaining ileum to 120 cm was normal. The patient has remained symptom-free and continues on the antibiotic regimen.

DETD As this study was continued, 35 patients with CD were being **treated** with RMAT. 37% (13/35) of the patients developed a serum sickness-like illness during the first 4-6 weeks of **treatment**. The patients experienced flu-like symptoms such as fever, chills, moderate to severe arthralgia, back pain, anorexia, and **fatigue**. These symptoms generally lasted for a full week and dissipated over the following 3 weeks. With each patient, a majority of symptoms stopped within the first month of **treatment**. It was also found that these symptoms responded well to Cox-2 inhibitors (**celecoxib** --200 mgm po qd) with no adverse effects or worsening of colitis noted during **treatment**. These observations suggest that the Cox-2 inhibitors may help in controlling the initial side effects of RMAT. It is also thought that this serum sickness may be a Jarisch-Herxheimer reaction in response to the antimicrobial therapy.

DETD Current hypotheses are being investigated regarding the causative agent(s) of Crohn's disease. While many workers in the field have become convinced of the involvement of *M. para.*, it may well turn out that this bacterium is but one of a number of pathogenic agents. Therefore, the regimen proposed herein preselects patients for antibiotic **treatment** by the detecting method of the present invention, the combined p35/p36 serological test, patients testing negative for *M. para.* being less likely to experience alleviation of CD symptoms under the antibiotic regimen.

DETD It may be appreciated by one skilled in the art that additional embodiments may be contemplated, including other recombinant clones chosen from the *M. paratuberculosis* genomic library and other antibiotic regimens for the **treatment** of bacteria-positive CD patients.

ACCESSION NUMBER: 2001:167903 USPATFULL

TITLE: Crohn's disease diagnostic and **treatment** methods and compositions

INVENTOR(S): Shafran, Ira, 1316 Greencove Rd., Winter Park, FL, United States 32789

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6297015	B1	20011002
APPLICATION INFO.:	US 1999-404095		19990923 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101579P	19980924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Le, Long V.	
ASSISTANT EXAMINER:	Cook, Lisa V	
LEGAL REPRESENTATIVE:	Allen, Dyer, Doppelt, Milbrath & Gilchrist, P.A.	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
LINE COUNT:	362	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

n complex to the antigen

composition, wherein the bound antibody-antigen complex detects a presence of *Mycobacterium avium* ss. *paratuberculosis*, and thus indicates a presence of Crohn's disease; administering a regimen of an antibiotic effective in and sufficient for eradicating a presence of *Mycobacterium paratuberculosis*; and administering a regimen of a probiotic and a specific carbohydrate diet.

9. The method recited in claim 1, further comprising the steps, following the administering step, of: determining whether a **treated** patient is experiencing a serum sickness-like illness; and if the determining step is positive, **treating** the patient with a Cox-2 inhibitor.

10. The method recited in claim 9, wherein the Cox-2 inhibitor comprises **celecoxib**.

11. The method recited in claim 10, wherein the **celecoxib** is administered in an oral dose of 200 mgm once per day.

12. A method for **treating** a human patient suspected of having Crohn's disease comprising the steps of: screening for Crohn's disease by performing an ELISA analysis for serum antibodies to *Mycobacterium avium* subspecies *paratuberculosis* (MAP); and for patients screening positive for MAP, administering a regimen of an antibiotic effective in and sufficient for eradicating a presence of *Mycobacterium paratuberculosis*.

IT 54-85-3, Isoniazid 57-92-1, Streptomycin, biological studies 74-55-5, Ethambutol 98-96-4, Pyrazinamide 8063-07-8, Kanamycin 13292-46-1, Rifampicin 72559-06-9, Rifabutin 81103-11-9, Clarithromycin 1695
90-42-5, Celecoxib
(antibiotic-based Crohn's disease treatment method, and *Mycobacterium avium* *paratuberculosis*-based diagnostic method)

ACCESSION NUMBER: 2002:336847 USPATFULL

TITLE: Crohn's disease **treatment** methods

INVENTOR(S): Shafran, Ira, Winter Park, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002192201	A1	20021219

APPLICATION INFO.: US 2002-165034 A1 20020607 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-968681, filed on 1 Oct 2001, PENDING Continuation-in-part of Ser. No. US 1999-404095, filed on 23 Sep 1999, GRANTED, Pat. No. US 6297015

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101579P	19980924 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Jacqueline E. Hartt, Allen, Dyer, Doppelt, Milbrath & Gilchrist, P.A., 255 South Orange Avenue, Suite 1401, P.O. Box 3791, Orlando, FL, 32802-3791

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

LINE COUNT: 465

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

n complex to the antigen

composition, wherein the bound antibody-antigen complex detects a presence of *Mycobacterium avium* ss. *paratuberculosis*, and thus indicates a presence of Crohn's disease; administering a regimen of an antibiotic effective in and sufficient for eradicating a presence of *Mycobacterium paratuberculosis*; and administering a regimen of a probiotic and a specific carbohydrate diet.

9. The method recited in claim 1, further comprising the steps, following the administering step, of: determining whether a **treated** patient is experiencing a serum sickness-like illness; and if the determining step is positive, **treating** the patient with a Cox-2 inhibitor.

10. The method recited in claim 9, wherein the Cox-2 inhibitor comprises **celecoxib**.

11. The method recited in claim 10, wherein the **celecoxib** is administered in an oral dose of 200 mgm once per day.

12. A method for **treating** a human patient suspected of having Crohn's disease comprising the steps of: screening for Crohn's disease by performing an ELISA analysis for serum antibodies to *Mycobacterium avium* subspecies *paratuberculosis* (MAP); and for patients screening positive for MAP, administering a regimen of an antibiotic effective in and sufficient for eradicating a presence of *Mycobacterium paratuberculosis*.

IT 54-85-3, Isoniazid 57-92-1, Streptomycin, biological studies 74-55-5, Ethambutol 98-96-4, Pyrazinamide 8063-07-8, Kanamycin 13292-46-1, Rifampicin 72559-06-9, Rifabutin 81103-11-9, Clarithromycin 1695
90-42-5, Celecoxib
(antibiotic-based Crohn's disease treatment method, and *Mycobacterium avium* paratuberculosis-based diagnostic method)

ACCESSION NUMBER: 2002:336847 USPATFULL

TITLE: Crohn's disease **treatment** methods

INVENTOR(S): Shafran, Ira, Winter Park, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002192201	A1	20021219
APPLICATION INFO.:	US 2002-165034	A1	20020607 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-968681, filed on 1 Oct 2001, PENDING Continuation-in-part of Ser. No. US 1999-404095, filed on 23 Sep 1999, GRANTED, Pat. No. US 6297015		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101579P	19980924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jacqueline E. Hartt, Allen, Dyer, Doppelt, Milbrath & Gilchrist, P.A., 255 South Orange Avenue, Suite 1401, P.O. Box 3791, Orlando, FL, 32802-3791	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	465	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

14. The method recited in claim 13, wherein the Cox-2 inhibitor comprises **celecoxib**.

15. The method recited in claim 13, wherein the **celecoxib** is administered in an oral dose of 200 mgm once per day.

ACCESSION NUMBER: 2002:198264 USPATFULL
TITLE: Crohn's disease **treatment** methods
INVENTOR(S): Shafran, Ira, Winter Park, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106357	A1	20020808
APPLICATION INFO.:	US 2001-968681	A1	20011001 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101579P	19980924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Allen, Dyer, Doppelt, Milbrath & Gilchrist, P.A., 255 South Orange Avenue, Suite 1401, P.O. Box 3791, Orlando, FL, 32802-3791	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	380	

-cyclooxygenase 2 inhibitor
antiangiogenic combination for treatment of cancer)
ACCESSION NUMBER: 2002:192070 USPATFULL
TITLE: Antiangiogenic combination therapy for the
treatment of cancer
INVENTOR(S): McKearn, John P., Wildwood, MO, UNITED STATES
Gordon, Gary B., Highland Park, IL, UNITED STATES
Cunningham, James, Chicago, IL, UNITED STATES
Gately, Stephen T., Palatine, IL, UNITED STATES
Koki, Alane T., Beaufort, MO, UNITED STATES
Masferrer, Jaime L., Ballwin, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103141	A1	20020801
APPLICATION INFO.:	US 2001-843132	A1	20010425 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-470951, filed on 22 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113786P	19981223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pharmacia Corporation, Corporate Patent Department, P.O. Box 5110, Chicago, IL, 60680-9889	
NUMBER OF CLAIMS:	181	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8069	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

and/or an effective amount of indomethacin. Of these two, metronidazole is preferred. The present invention is further directed to methods of **treating** smooth muscle contraction, including the contraction of the uterus during, for instance, premature labor. The methods include administering a composition to a subject who has or is at risk of developing smooth muscle contractions a composition comprising an amount of a heterocycle-containing compound effective to prevent, or control by extending to substantially full-term, a premature labor. The heterocycle-containing compound present in the composition is a diphenyl heterocycle derivative, a prostaglandin analog, or a combination thereof.

DETD [0076] The present invention is also directed to methods for modifying inflammatory responses that are mediated by PGE₂. Prostaglandins, for instance PGE₂, and leukotrienes (for instance LTB₄), are known to arise during inflammation. In high levels, PGE₂ is pro-inflammatory because it stimulates synthesis of IL-8, while in low levels, it can be cytoprotective, because of its capacity to stimulate cytokine IL-10 production. The latter cytokine (IL-10) downregulates inflammation, while the former (IL-8) signals the infiltration of polymorphonuclear neutrophils (a type of leukocyte) into the affected tissue. PGE₂ is typically produced by a cell, for instance a damaged cell, is released by the cell and interacts with a receptor on a second cell. The second cell may be a leukocyte whose function is to release substances toxic for microorganisms. These substances include reactive oxygen species (including free hydroxyls, superoxide anion, and singlet oxygen), proteolytic enzymes, and acids. While toxic to microorganisms, they are also very toxic for the host's own tissues. It is expected that the prostaglandin analogs of the present invention, preferably PGE₂-imidazole or PGE₂-histidine, will bind to PGE₂ receptors and inhibit the binding of PGE₂, and possibly other prostaglandins. It is further expected that the binding of PGE₂-imidazole or PGE₂-histidine to a PGE₂ receptor will not cause a response in the cell that includes the receptor. Examples of conditions that can be **treated** by modifying inflammatory responses that are mediated by PGE₂ include, for instance, colibacillosis and mastitis in cattle, pancreatitis, Barrett's esophagus, gastroesophageal reflux disease syndrome (GERDS), and hepatitis.

DETD [0111] Considering that purified PGE₂-imidazole inhibited cAMP formation in CT-stimulated CHO cells (FIG. 4), the capacity of this adduct to block CT-induced fluid accumulation in murine intestinal loops was tested. FIG. 5A shows that PGE₂-imidazole, in doses as low as 100 μ g, instilled into the intestinal lumen significantly reduced CT-induced fluid accumulation. A dose of 200 μ g completely blocked fluid loss following CT challenge during the 6-hour observation period. The cAMP levels (FIG. 5B) in the intestinal loop fluids were markedly reduced by PGE₂-imidazole **treatment** and coincided with the reduction in fluid accumulation.

DETD [0122] Mouse intestinal loops challenged with CT and dosed with L-histidine accumulated significantly less fluid than those from the corresponding CT-challenged control mice (FIG. 1). Generally, the observed dose of L-histidine, providing mouse intestinal loops with maximum protection against CT-induced fluid accumulation, was relatively large (592 mg/kg), even when **treatment** was initiated at the same time as toxin challenge (FIG. 1).

DETD [0124] L-histidine was demonstrated to react chemically with PGE₂ (FIG. 3), and we considered the possibility that L-histidine inhibited the action of PGE₂ in murine intestinal loops challenged with CT. It was demonstrated that the purified PGE₂-imidazole adduct reduced cAMP levels in culture supernatants of CHO cells stimulated with CT (FIG. 4). It was surmised that L-histidine, as well as the PGE₂-imidazole adduct, interfered with the activity of PGE₂ in the CT-**treated** cells. It was not possible to measure the reduction of PGE₂ *in vivo* or *in vitro* by PGE₂-specific

radioimmunoassays, since the PGE₂-histidine (or imidazole) adduct appeared to react equally well with antibodies to PGE₂. In part, L-histidine could have served as a PGE₂-inactivating compound, which provided additional support for the role of PGE₂ in CT-induced secretion of water and electrolytes in the small intestine. Additionally, the PGE₂-histidine covalent adduct could serve to inhibit the potential of PGE₂ to stimulate adenylyl cyclase. Indeed, purified PGE₂-imidazole adduct inhibited CT-induced fluid accumulation in murine intestinal loops (FIG. 5A). In this case, the imidazole moiety may inactivate the native stimulatory effect of PGE₂ on ion transport, but it is likely the structural similarity of the PGE₂-adduct to PGE₂ that enables it to interfere with the action of CT-induced PGE₂ and fluid accumulation. Other PGE₂ analogs (e.g., PGA₂ and PGB₂) also reduce CT-induced fluid accumulation in murine intestinal loops with lower potency.

DETD [0130] Adult female Swiss-Webster mice (25-30 g) were purchased from Taconic Farms, Inc. (Germantown, N.Y.) and housed in a specific pathogen-free animal facility at UTMB in Galveston, Tex. Mice were fasted for 18 hr before surgery to reduce the food content of the small intestine. A ventral midline incision was made under ether anesthesia to expose the small intestine. A single 5-cm segment of small intestine, ligated with "00" silk suture, was injected with 1 μ g of cholera toxin (CT) in 100 μ l. After 6 hours observation, the animals were euthanized by cervical dislocation and the intestinal loops were removed. The amount of luminal fluid was measured and expressed as μ l/cm, while the tissue was prepared for light or electron microscopy. In some experiments, intestinal challenge was accomplished by injecting 100 μ g of CT followed immediately with 160 μ g/100 μ l **celecoxib** (dissolved in 3% dimethylsulfoxide in phosphate buffered saline) at the time of challenge. Fluid volume was measured 6 hours after challenge. Specimens of fluid and tissue were collected at time of necropsy.

DETD [0131] The inhibitory effect on CT-induced fluid accumulation was observed with dosages of **celecoxib** reported to be specific for COX-2.

DETD [0133] FIG. 11 shows that CT-induced fluid accumulation in murine intestinal loops is significantly reduced by **celecoxib**.

DETD [0142] The results indicate that **celecoxib**, PGE₂-histidine, and imidazole each inhibit adenylyl cyclase enzyme activity (FIG. 12). The data in FIG. 12 also show the absence of adenylyl cyclase inhibition by SC560 and **rofecoxib** under the conditions tested. FIG. 13 shows that SC560 inhibits cholera toxin-induced fluid secretion, although it has not been demonstrated that it does so by inhibiting adenylyl cyclase under the conditions tested (FIG. 12). **Rofecoxib** does not inhibit cholera toxin-induced secretion under the conditions tested. **Celecoxib** was designed to be a highly specific inhibitor of cyclooxygenase-2 (COX-2). The mechanism by which **celecoxib** inhibits adenylyl cyclase is not known; however, it was observed that imidazole also inhibits adenylyl cyclase. Since imidazole is part of the chemical structure of **celecoxib**, it is suspected that this moiety participates in the functional activity of inhibiting adenylyl cyclase. Imidazole is known to bind divalent cations (e.g., Mg⁺⁺, Zn⁺⁺, and Ca⁺⁺), and these metal cations are known to be required for adenylyl cyclase activity. In fact, a recent report in which the X-ray crystallography-derived structure of rat adenylyl cyclase was determined showed that there were two binding domains in the catalytic site of adenylyl cyclase divalent cations (Zn⁺⁺ and Mg⁺⁺). We suspect that the imidazole group of **celecoxib** is enabling the drug to bind to the metal ions in the enzyme's active site, which would block the substrate (ATP) from entering. The end result would be inhibition of adenylyl cyclase activity. From a physiological perspective in the small intestine, such an inhibitor would reduce or block cholera toxin-induced fluid loss (**diarrhea**).

DETD [0145] The adenylate cyclase enzyme assay was performed as described earlier in Example 1; however, the assay was used to assay various inhibitors (e.g., PGE₂-histidine, **celecoxib**, and imidazole). The amount of enzyme in each experiment was 0.46 nmole, and the concentration of each inhibitor was varied in order to determine the dose that would block 50% of the enzyme activity (IC₅₀).

DETD [0147] The results summarized in the FIGS. 14-16 indicate that adenylate cyclase can be inhibited, which forms a strategy for reducing or blocking intestinal fluid secretion induced by several agents of diarrheal disease. FIG. 14 shows the dose response for PGE₂-histidine in inhibiting adenylate cyclase. The IC₅₀ dose of PGE₂-histidine inhibiting 50% of the enzyme activity (0.46 nmole) was 21.5 μ mole. FIG. 15 shows that when a similar experiment was performed with **celecoxib**, and its IC₅₀ dose was 20 mmole. FIG. 16 shows that imidazole alone exhibited inhibited adenylate cyclase activity; however, it was less potent (IC₅₀=1.57 mmole). Table 1 summarizes the inhibitory potencies of the various adenylate cyclase inhibitors. Similar results were observed when edema factor from *B. anthracis* was used as the adenylate cyclase.

TABLE 1

Molar concentration of commonly available drugs required to inhibit Adenylate Cyclase

Enzyme:Drug	Ratio
Adenylate Cyclase: Celecoxib	0.46 nm:20.0 μ m
Adenylate Cyclase:Imidazole	0.46 nm:1.57 mm
Adenylate Cyclase:Histidine:PGE ₂ Adduct	0.46 nm:21.5 μ m

CLM What is claimed is:

8. The method of claim 6 wherein the diphenyl heterocycle derivative is **celebrex** or DuP-697.

16. The method of claim 15 wherein the diphenyl heterocycle derivative is **celebrex** or DuP-697.

24. A method for **treating** intestinal fluid loss in a subject, the method comprising administering to a subject who has or is at risk of developing intestinal fluid loss a composition comprising an effective amount of a heterocycle derivative selected from the group consisting of a diphenyl heterocycle derivative, a prostaglandin analog, and a combination thereof, wherein the fluid loss is not associated with a pathogen polypeptide having ADP-ribosylation activity.

35. A method for **treating** intestinal fluid loss in a subject, the method comprising administering to a subject who has or is at risk of developing intestinal fluid loss a composition comprising an effective amount of a heterocycle-containing compound, wherein the intestinal fluid loss is associated with a pathogen polypeptide having ADP-ribosylation activity.

43. The method of claim 35 wherein the heterocycle derivative is not **celecoxib**.

47. A method for **treating** whooping cough in a subject, the method comprising administering to a subject who has or is at risk of developing whooping cough a composition comprising an effective amount of an heterocycle-containing compound.

55. A method for **treating** anthrax in a subject, the method comprising administering to a subject who has or is at risk of developing anthrax a composition comprising an effective amount of a heterocycle-containing compound.

IT 53-86-1, Indomethacin 71-00-1, L-Histidine, biological studies
288-32-4, Imidazole, biological studies 443-48-1, Metronidazole
88149-94-4 162011-90-7 169590-42-5 188817-13-2
(heterocycle derivs. for inhibiting adenylyl cyclase and methods of
use for treating intestinal fluid loss and whooping cough and anthrax
and conditions assocd. with smooth muscle contraction)

ACCESSION NUMBER: 2002:55065 USPATFULL
TITLE: Heterocycle derivatives and methods of use
INVENTOR(S): Peterson, Johnny W., Dickinson, TX, UNITED STATES
Gessell-Lee, Deborah L., Galveston, TX, UNITED STATES
Saini, Shamsher S., Dickinson, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032228	A1	20020314
	US 2002188016	A9	20021212
APPLICATION INFO.:	US 2001-860652	A1	20010519 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-210412P	20000608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458	
NUMBER OF CLAIMS:	62	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	1668	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L200 ANSWER 6 OF 36 USPATFULL

TI Crohn's disease diagnostic and **treatment** methods and
compositions

AB A composition and method for detecting Crohn's disease include the use
of serological testing as a rapid and simple way to diagnose Crohn's
disease. The serological tests were based on the use of the two
recombinant clones isolated from an *M. paratuberculosis* genomic library
that expressed 35K and 36K MW antigens. Antigen p35 was isolated from
Johne's disease sera (acid-fast bacilli form) and p36, from human CD
sera (spheroplast form). The combined use of p35 and p36 recombinant
antigens provides a highly specific and sensitive test to demonstrate
the humoral immune response of CD patients to *M. paratuberculosis*. A
serologic kit is disclosed including the composition including the
combined p35 and p36 antigens. A **treatment** methodology
utilizes antimycobacterial drugs, preferably upon patients prescreened
for the presence of *M. para*. A particular antibiotic regimen includes an
administration of both rifabutin and clarithromycin, which has been
found to be particularly effective in alleviating the symptoms of
Crohn's disease.

SUMM The present invention relates to compositions and methods for diagnosing
and **treating** Crohn's disease, and, more particularly, to such
compositions and methods for screening for a presence of a bacterium
believed involved in causing Crohn's disease and for **treating**
patients shown by the screening method to be infected with the
bacterium.

SUMM Common symptoms of Crohn's disease include abdominal pain and
diarrhea. There may also be **rectal bleeding**,
weight loss, and fever. The bleeding may be serious and persistent,
leading to anemia. Children may suffer delayed development and stunted
growth.